

Table I-1

ESTIMATED NEW CANCER CASES AND DEATHS FOR 2004

All Races, By Sex

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Males	Females	Total	Males	Females
All Sites	1,368,030	699,560	668,470	563,700	290,890	272,810
Oral Cavity and Pharynx	28,260	18,550	9,710	7,230	4,830	2,400
Tongue	7,320	4,860	2,460	1,700	1,100	600
Mouth	10,080	5,410	4,670	1,890	1,070	820
Pharynx	8,250	6,330	1,920	2,070	1,460	610
Other Oral Cavity	2,610	1,950	660	1,570	1,200	370
Digestive System	255,640	135,410	120,230	134,840	73,240	61,600
Esophagus	14,250	10,860	3,390	13,300	10,250	3,050
Stomach	22,710	13,640	9,070	11,780	6,900	4,880
Small Intestine	5,260	2,750	2,510	1,130	610	520
Colon	106,370	50,400	55,970			
Rectum ^a	40,570	23,220	17,350	56,730 ^a	28,320 ^a	28,410 ^a
Anus, Anal Canal, and Anorectum	4,010	1,890	2,120	580	210	370
Liver and Intrahepatic Bile Duct	18,920	12,580	6,340	14,270	9,450	4,820
Gallbladder and Other Biliary	6,950	2,960	3,990	3,540	1,290	2,250
Pancreas	31,860	15,740	16,120	31,270	15,440	15,830
Other Digestive	4,740	1,370	3,370	2,240	770	1,470
Respiratory System	186,550	102,730	83,820	165,130	95,460	69,670
Larynx	10,270	8,060	2,210	3,830	3,010	820
Lung and Bronchus	173,770	93,110	80,660	160,440	91,930	68,510
Other Respiratory	2,510	1,560	950	860	520	340
Bones and Joints	2,440	1,230	1,210	1,300	720	580
Soft Tissue	8,680	4,760	3,920	3,660	2,020	1,640
Skin (excl. basal & squamous)	59,350	31,640	27,710	10,250	6,590	3,660
Melanoma of the Skin ^b	55,100	29,900	25,200	7,910	5,050	2,860
Other non-epithelial skin	4,910	2,400	2,510	2,340	1,540	800
Breast ^b	217,440	1,450	215,990	40,580	470	40,110
Genital Organs	323,210	240,660	82,550	59,250	30,530	28,720
Cervix (uterus)	10,520		10,520	3,900		3,900
Endometrium (uterus)	40,320		40,320	7,090		7,090
Ovary	25,580		25,580	16,090		16,090
Vulva	3,970		3,970	850		850
Vagina and other genital organs, female	2,160		2,160	790		790
Prostate	230,110	230,110		29,900	29,900	
Testis	8,980	8,980		360	360	
Penis and other genital organs, male	1,570	1,570		270	270	
Urinary System	98,400	68,290	30,110	25,880	17,060	8,820
Urinary Bladder	60,240	44,640	15,600	12,710	8,780	3,930
Kidney and Renal Pelvis	35,710	22,080	13,630	12,480	7,870	4,610
Ureter and other urinary organs	2,450	1,570	880	690	410	280
Eye and Orbit	2,090	1,130	960	180	110	70
Brain and Other Nervous System	18,400	10,540	7,860	12,690	7,200	5,490
Endocrine System	25,520	6,950	18,570	2,440	1,140	1,300
Thyroid	23,600	5,960	17,640	1,460	620	840
Other Endocrine	1,920	990	930	980	520	460
Lymphoma	62,250	33,180	29,070	20,730	11,090	9,640
Hodgkin Lymphoma	7,880	4,330	3,550	1,320	700	620
Non-Hodgkin Lymphoma	54,370	28,850	25,520	19,410	10,390	9,020
Myeloma	15,270	8,090	7,180	11,070	5,430	5,640
Leukemia	33,440	19,020	14,420	23,300	12,990	10,310
Lymphocytic Leukemias	12,020	7,160	4,860	6,250	3,550	2,700
Myeloid Leukemias	16,520	8,980	7,540	10,440	5,750	4,690
Other leukemia	4,900	2,880	2,020	6,610	3,690	2,920
All Other Sites ^c	31,090	15,930	15,160	45,170	22,010	23,160

Cancer Facts & Figures - 2004, American Cancer Society (ACS), Atlanta, Georgia, 2004.
Excludes basal and squamous cell skin and *in situ* carcinomas except urinary bladder.
Incidence projections are based on rates from the NCI SEER Program 1979-2000.

^a

Estimated deaths for colon & rectum cancers are combined.

^b

Carcinoma *in situ* of the breast accounts for about 59,390 new cases annually, and melanoma *in situ* accounts for about 40,780 new cases annually.

^c

More deaths than cases suggests lack of specificity in recording underlying causes of death on death certificate.

Table I-2

52-YEAR TRENDS IN U.S. CANCER DEATH RATES^a

All Races, Males and Females

All Primary Cancer Sites Combined

Age Group	1950	1975	2001	Annual Percent Change		Total Percent Change
				1950-1975	1975-2001	1950-2001
0-4	11.1	5.2	2.5	-2.8	-2.9	-77.4
5-14	6.7	4.8	2.5	-1.0	-2.8	-63.2
15-24	8.6	6.6	4.2	-0.7	-1.7	-50.5
25-34	20.4	15.1	10.0	-1.2	-1.4	-50.9
35-44	63.6	53.3	36.7	-0.4	-1.4	-42.4
45-54	174.2	178.0	126.0	0.2	-1.4	-27.7
55-64	391.3	420.2	357.3	0.3	-0.6	-8.7
65-74	710.0	778.7	802.9	0.4	0.2	13.1
75-84	1,167.2	1,160.9	1,311.9	0.0	0.5	12.4
85+	1,450.7	1,437.9	1,747.9	-0.2	0.7	20.5
All Ages	195.4	199.1	195.6	0.1	-0.1	0.1

Lung and Bronchus Cancer^b

Age Group	1950	1975	2001	Annual Percent Change		Total Percent Change
				1950-1975	1975-2001	1950-2001
0-4	-	-	-	-	-	-
5-14	-	-	-	-	-	-
15-24	0.2	0.1	-	-2.5	-1.0	-68.0
25-34	0.8	0.9	0.4	0.4	-1.8	-51.3
35-44	4.6	10.6	6.2	3.7	-2.4	35.1
45-54	20.2	48.8	30.6	3.6	-2.1	51.3
55-64	48.9	122.6	118.2	3.6	-0.1	141.9
65-74	59.4	196.2	280.2	4.5	1.3	371.5
75-84	55.4	192.3	372.3	5.3	2.4	572.2
85+	42.3	135.5	300.7	5.1	3.0	611.0
All Ages	14.9	42.8	55.4	4.2	0.9	270.5

Source: NCHS public use data file for the total US.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups.^b Due to coding changes throughout the years, Lung and Bronchus includes trachea and pleura.

Table I-3

SUMMARY OF CHANGES IN CANCER INCIDENCE AND MORTALITY, 1950-2001 AND

5-YEAR RELATIVE SURVIVAL RATES, 1950-2000

Males and Females, By Primary Cancer Site

Table is temporarily unavailable.

Table I-4
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Incidence ^a (1997-2001)			US Mortality ^b (1997-2001)			Survival ^c (1995-2000)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
	All Races	470.3	554.3	414.4	199.8	251.1	166.7	64.1	64.0
Oral Cavity & Pharynx:	10.7	15.7	6.4	2.8	4.3	1.6	58.7	57.4	61.5
Lip	1.0	1.7	0.4	0.0	0.0	0.0	93.0	94.2	87.7
Tongue	2.5	3.7	1.6	0.7	1.0	0.4	55.7	55.2	56.8
Salivary gland	1.2	1.6	1.0	0.2	0.4	0.2	75.6	70.9	80.3
Floor of mouth	0.8	1.2	0.5	0.1	0.1	0.0	51.3	49.6	54.6
Gum & other oral cavity	1.7	2.0	1.4	0.5	0.6	0.3	57.9	52.2	65.4
Nasopharynx	0.7	1.0	0.4	0.2	0.4	0.1	57.6	58.2	56.5
Tonsil	1.3	2.1	0.5	0.2	0.3	0.1	58.8	58.5	59.5
Oropharynx	0.3	0.5	0.2	0.2	0.3	0.1	38.0	36.9	41.5
Hypopharynx	0.8	1.4	0.3	0.1	0.2	0.1	30.2	30.9	28.1
Other oral cavity & pharynx	0.3	0.4	0.2	0.6	1.0	0.3	31.6	32.4	29.7
Digestive System:	91.5	112.6	75.3	47.4	60.8	37.4	44.4	42.6	46.5
Esophagus	4.5	7.7	2.0	4.4	7.7	1.8	14.3	14.2	14.7
Stomach	8.9	12.6	6.1	4.7	6.6	3.3	23.3	22.1	25.4
Small intestine	1.7	2.0	1.5	0.4	0.5	0.3	53.1	52.6	53.5
Colon & Rectum:	53.7	63.4	46.4	20.8	25.3	17.7	63.4	63.7	63.1
Colon	38.8	44.3	34.8	17.8	21.3	15.3	63.0	63.9	62.2
Rectum	14.8	19.1	11.6	3.0	3.9	2.3	64.3	63.2	65.6
Anus, anal canal & anorectum	1.3	1.3	1.4	0.2	0.1	0.2	67.8	60.8	73.2
Liver & Intrahep:	6.0	9.1	3.5	4.6	6.7	2.9	8.3	7.7	9.6
Liver	5.1	8.0	2.8	3.7	5.6	2.1	8.9	8.0	11.1
Intrahep bile duct	0.9	1.1	0.7	0.9	1.1	0.8	4.8	4.9	4.6
Gallbladder	1.2	0.8	1.6	0.7	0.5	0.9	15.2	15.6	15.0
Other biliary	1.6	2.0	1.3	0.6	0.7	0.5	20.2	21.9	17.9
Pancreas	11.0	12.6	9.7	10.5	12.2	9.2	4.4	4.2	4.6
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	47.5	43.2	51.0
Peritoneum, omentum & mesentery	0.7	0.2	1.0	0.2	0.1	0.3	32.1	20.5	34.6
Other digestive system	0.5	0.5	0.4	0.3	0.3	0.2	9.5	5.9	12.6
Respiratory System:	67.3	88.7	51.5	58.0	81.0	41.6	18.7	18.5	19.0
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.2	0.2	0.1	52.6	51.3	54.4
Larynx	3.8	6.7	1.4	1.4	2.6	0.5	65.1	66.7	59.6
Lung & bronchus	61.7	79.1	49.1	56.2	77.9	40.8	15.2	13.6	17.2
Pleura	0.9	1.8	0.3	0.1	0.2	0.0	7.8	7.1	10.5
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	43.7	43.5	43.4
Bones & joints	0.9	1.0	0.8	0.4	0.6	0.4	69.6	67.7	72.3
Soft tissue (incl heart)	2.9	3.5	2.4	1.4	1.6	1.3	67.6	67.9	67.2
Skin (ex basal & squam):	19.6	25.3	15.4	3.5	5.3	2.2	86.7	82.9	91.7
Melanoma of the skin	17.0	21.4	13.8	2.7	3.9	1.8	90.5	89.0	92.2
Other non-epithelial skin	2.6	3.9	1.5	0.8	1.4	0.4	66.2	59.1	86.9
Breast	73.9	1.2	135.2	15.3	0.3	27.0	87.6	81.1	87.7
Breast (<i>in situ</i>)	16.1	0.2	30.0	-	-	-	100.0	100.0	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

^a SEER 12 areas.

^b NCHS public use data file for the total US.

^c SEER 9 areas.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-4 - continued
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	All Races								
	Incidence ^a (1997-2001)			US Mortality ^b (1997-2001)			Survival ^c (1995-2000)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.8	-	51.3	9.5	-	16.7	70.4	-	70.4
Cervix uteri	4.8	-	9.3	1.6	-	2.9	72.7	-	72.7
Corpus uteri	13.1	-	24.0	1.2	-	2.0	85.3	-	85.3
Uterus, NOS	0.3	-	0.4	1.2	-	2.1	27.1	-	27.1
Ovary	7.6	-	13.9	5.0	-	8.9	44.0	-	44.0
Vagina	0.4	-	0.7	0.1	-	0.3	44.7	-	44.7
Vulva	1.3	-	2.3	0.3	-	0.4	76.9	-	76.9
Other female genital system	0.4	-	0.7	0.1	-	0.2	62.1	-	62.1
Male Genital System:	78.2	178.7	-	11.8	32.0	-	99.0	99.0	-
Prostate	75.0	172.3	-	11.6	31.5	-	99.3	99.3	-
Testis	2.6	5.2	-	0.1	0.3	-	95.9	95.9	-
Penis	0.3	0.8	-	0.1	0.2	-	75.5	75.5	-
Other male genital system	0.2	0.4	-	0.0	0.0	-	74.5	74.5	-
Urinary System:	32.6	53.1	17.4	8.8	14.0	5.3	74.6	76.8	69.8
Urinary bladder	20.4	36.1	9.1	4.4	7.6	2.3	81.7	83.7	76.2
Kidney & renal pelvis	11.3	15.7	7.8	4.2	6.1	2.8	63.9	63.9	63.9
Ureter	0.5	0.8	0.4	0.1	0.2	0.1	54.5	55.7	52.9
Other urinary system	0.3	0.5	0.2	0.1	0.1	0.1	59.4	71.6	39.0
Eye & Orbit	0.7	0.9	0.6	0.1	0.1	0.1	81.4	84.2	78.3
Brain & Nervous System: ^d	6.4	7.6	5.3	4.6	5.6	3.8	33.0	32.7	33.4
Brain	6.0	7.2	4.9	-	-	-	30.3	30.0	30.7
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	74.6	77.4	71.1
Endocrine System:	7.8	4.5	11.0	0.8	0.8	0.8	93.4	88.1	95.2
Thyroid	7.2	3.8	10.4	0.5	0.4	0.5	96.5	93.4	97.3
Other endocrine & thymus	0.6	0.7	0.6	0.3	0.4	0.3	60.8	62.7	58.6
Lymphoma:	21.7	26.2	18.1	8.9	11.1	7.3	63.3	61.2	65.8
Hodgkin lymphoma	2.7	3.0	2.4	0.5	0.6	0.4	85.2	83.9	86.8
Non-Hodgkin lymphoma	19.1	23.3	15.7	8.4	10.5	6.9	59.1	57.0	61.7
Myeloma	5.6	6.9	4.6	3.8	4.7	3.2	32.1	35.6	28.4
Leukemia:	12.1	15.9	9.4	7.6	10.2	5.9	46.4	47.0	45.7
Lymphocytic:	5.5	7.4	4.1	2.2	3.2	1.6	70.4	69.8	71.2
Acute lymphocytic	1.5	1.7	1.4	0.5	0.6	0.4	64.8	64.6	65.2
Chronic lymphocytic	3.5	5.0	2.4	1.6	2.3	1.1	72.7	70.6	75.6
Other lymphocytic	0.5	0.7	0.3	0.1	0.2	0.1	77.8	82.0	67.1
Myeloid & Monocytic:	5.8	7.5	4.7	3.5	4.5	2.8	24.6	24.3	25.1
Acute myeloid	3.8	4.7	3.1	2.6	3.3	2.1	19.5	18.3	20.8
Chronic myeloid	1.6	2.2	1.2	0.7	0.9	0.6	36.7	36.9	36.5
Acute monocytic	0.3	0.3	0.2	0.0	0.1	0.0	15.6	16.3	15.5
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.1	26.7	25.9	26.4
Other:	0.8	1.0	0.7	1.9	2.5	1.5	15.4	16.5	14.3
Other acute	0.4	0.5	0.4	0.9	1.2	0.7	7.3	7.1	7.6
Aleukemic, subleuk & NOS	0.4	0.5	0.3	1.0	1.3	0.8	26.6	30.3	23.3
Ill-defined & unspecified	10.8	12.4	9.7	14.9	18.6	12.4	14.6	17.3	12.3

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

^a SEER 12 areas.

^b NCHS public use data file for the total US.

^c SEER 9 areas.

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-5
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence ^a (1997-2001)			US Mortality ^b (1997-2001)			Survival ^c (1995-2000)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	479.6	556.5	429.8	196.9	245.5	165.5	65.5	65.5	65.5
Oral Cavity & Pharynx:	10.7	15.7	6.4	2.6	3.9	1.6	60.9	60.4	62.0
Lip	1.1	2.0	0.4	0.0	0.1	0.0	93.4	94.4	88.8
Tongue	2.6	3.8	1.6	0.6	0.9	0.4	57.1	57.4	56.5
Salivary gland	1.3	1.7	1.0	0.3	0.4	0.2	74.9	70.1	79.2
Floor of mouth	0.8	1.2	0.5	0.1	0.1	0.0	53.0	52.4	54.0
Gum & other oral cavity	1.7	2.0	1.4	0.5	0.6	0.3	60.1	56.2	64.9
Nasopharynx	0.4	0.6	0.2	0.2	0.3	0.1	53.0	50.4	57.8
Tonsil	1.3	2.2	0.6	0.2	0.3	0.1	62.2	62.4	61.3
Oropharynx	0.3	0.5	0.2	0.2	0.3	0.1	40.7	38.9	45.4
Hypopharynx	0.8	1.4	0.3	0.1	0.2	0.1	32.3	33.5	29.4
Other oral cavity & pharynx	0.3	0.4	0.2	0.5	0.9	0.3	34.2	35.5	31.3
Digestive System:	88.3	108.5	72.7	45.5	58.4	35.8	45.8	44.0	47.8
Esophagus	4.5	7.7	1.9	4.2	7.4	1.7	15.8	15.6	16.3
Stomach	7.5	10.8	5.0	4.1	5.8	2.8	21.5	19.9	24.0
Small intestine	1.6	1.9	1.4	0.4	0.5	0.3	54.9	54.5	55.3
Colon & Rectum:	53.3	63.1	45.9	20.3	24.8	17.1	64.1	64.3	63.8
Colon	38.6	44.2	34.4	17.3	20.9	14.8	63.8	64.7	63.0
Rectum	14.8	18.9	11.5	3.0	3.9	2.3	64.6	63.6	65.9
Anus, anal canal & anorectum	1.4	1.3	1.5	0.2	0.1	0.2	69.3	62.9	74.1
Liver & Intrahep:	4.8	7.2	2.9	4.2	6.1	2.7	8.0	7.0	10.2
Liver	4.0	6.2	2.2	3.3	5.0	1.9	8.9	7.3	12.6
Intrahep bile duct	0.8	1.1	0.7	0.9	1.1	0.8	4.6	5.0	4.2
Gallbladder	1.2	0.8	1.5	0.7	0.5	0.9	15.0	16.7	14.3
Other biliary	1.5	1.9	1.2	0.6	0.7	0.5	19.8	22.9	16.1
Pancreas	10.8	12.5	9.4	10.3	12.0	8.9	4.2	4.3	4.2
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	50.1	45.8	53.8
Peritoneum, omentum & mesentery	0.7	0.2	1.1	0.2	0.1	0.3	30.7	15.9	33.8
Other digestive system	0.5	0.5	0.4	0.3	0.3	0.2	10.4	5.7	14.4
Respiratory System:	68.0	87.6	53.8	57.9	79.6	42.4	19.0	18.8	19.1
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.2	0.2	0.1	56.2	56.0	56.4
Larynx	3.8	6.6	1.5	1.3	2.3	0.5	67.4	68.9	62.0
Lung & bronchus	62.4	77.9	51.3	56.2	76.6	41.6	15.4	13.7	17.4
Pleura	1.0	1.9	0.3	0.1	0.3	0.1	7.9	7.4	10.0
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	45.0	45.5	44.3
Bones & joints	0.9	1.1	0.8	0.5	0.6	0.4	70.0	67.8	73.0
Soft tissue (incl heart)	2.9	3.5	2.5	1.4	1.6	1.2	69.0	69.6	68.3
Skin (ex basal & squam):	22.9	29.2	18.4	3.9	5.8	2.5	87.7	84.3	92.0
Melanoma of the skin	20.3	25.4	16.8	3.0	4.4	2.0	90.7	89.1	92.4
Other non-epithelial skin	2.6	3.9	1.6	0.9	1.5	0.4	68.3	61.5	87.3
Breast	76.8	1.2	141.7	15.0	0.3	26.4	88.9	84.3	88.9
Breast (<i>in situ</i>)	16.4	0.2	31.0	-	-	-	100.0	100.0	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

^a SEER 12 areas.

^b NCHS public use data file for the total US.

^c SEER 9 areas.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-5 - continued
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence ^a (1997-2001)			US Mortality ^b (1997-2001)			Survival ^c (1995-2000)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	28.9	-	53.8	9.3	-	16.5	71.4	-	71.4
Cervix uteri	4.6	-	8.9	1.4	-	2.6	74.0	-	74.0
Corpus uteri	13.9	-	25.7	1.1	-	1.9	86.9	-	86.9
Uterus, NOS	0.2	-	0.4	1.1	-	1.9	29.0	-	29.0
Ovary	8.0	-	14.8	5.2	-	9.2	44.0	-	44.0
Vagina	0.4	-	0.7	0.1	-	0.2	41.8	-	41.8
Vulva	1.4	-	2.5	0.3	-	0.5	77.3	-	77.3
Other female genital system	0.4	-	0.7	0.1	-	0.2	60.5	-	60.5
Male Genital System:	77.1	174.7	-	10.9	29.3	-	99.8	99.8	-
Prostate	73.5	167.4	-	10.6	28.8	-	100.0	100.0	-
Testis	3.2	6.2	-	0.1	0.3	-	96.2	96.2	-
Penis	0.3	0.8	-	0.1	0.2	-	76.6	76.6	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	80.5	80.5	-
Urinary System:	35.0	57.4	18.4	9.0	14.4	5.3	75.8	78.0	70.7
Urinary bladder	22.5	39.9	9.8	4.5	7.9	2.3	82.7	84.6	77.4
Kidney & renal pelvis	11.7	16.2	8.1	4.3	6.2	2.8	63.9	64.1	63.6
Ureter	0.6	0.8	0.4	0.1	0.2	0.1	57.7	59.7	54.8
Other urinary system	0.3	0.5	0.1	0.1	0.1	0.1	62.8	71.9	44.6
Eye & Orbit	0.9	1.0	0.7	0.1	0.1	0.1	81.5	84.4	78.2
Brain & Nervous System: ^d	7.1	8.4	6.0	4.9	6.0	4.0	32.2	32.0	32.5
Brain	6.7	8.0	5.5	-	-	-	29.4	29.1	29.8
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	77.9	80.6	74.2
Endocrine System:	8.1	4.7	11.5	0.8	0.8	0.7	93.9	88.7	95.6
Thyroid	7.5	4.0	10.9	0.5	0.5	0.4	96.8	93.8	97.6
Other endocrine & thymus	0.6	0.7	0.5	0.3	0.4	0.3	60.5	61.1	59.7
Lymphoma:	23.0	27.6	19.2	9.2	11.4	7.6	64.4	62.6	66.6
Hodgkin lymphoma	2.9	3.3	2.6	0.5	0.6	0.4	85.9	84.5	87.5
Non-Hodgkin lymphoma	20.1	24.4	16.6	8.7	10.8	7.2	60.3	58.4	62.6
Myeloma	5.2	6.6	4.2	3.5	4.4	2.9	31.9	35.2	28.3
Leukemia:	12.9	16.9	9.9	7.8	10.5	6.0	47.8	48.1	47.3
Lymphocytic:	6.0	8.1	4.4	2.3	3.3	1.6	71.7	71.0	72.7
Acute lymphocytic	1.6	1.8	1.5	0.5	0.6	0.4	66.0	65.4	66.8
Chronic lymphocytic	3.9	5.5	2.7	1.6	2.4	1.1	73.8	71.6	76.7
Other lymphocytic	0.5	0.8	0.3	0.2	0.2	0.1	80.2	84.3	69.1
Myeloid & Monocytic:	6.0	7.7	4.8	3.6	4.6	2.9	24.2	23.7	25.0
Acute myeloid	3.9	4.9	3.2	2.6	3.4	2.1	18.7	17.5	20.0
Chronic myeloid	1.7	2.2	1.3	0.7	0.9	0.6	36.8	36.4	37.6
Acute monocytic	0.3	0.4	0.2	0.1	0.1	0.0	17.8	19.5	15.4
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.1	29.1	26.1	31.3
Other:	0.8	1.1	0.7	1.9	2.6	1.5	15.5	16.1	14.9
Other acute	0.4	0.6	0.4	1.0	1.3	0.8	6.8	5.6	8.0
Aleukemic, subleuk & NOS	0.4	0.5	0.3	1.0	1.3	0.8	28.2	31.9	24.6
Ill-defined & unspecified	10.8	12.3	9.7	14.7	18.2	12.2	15.2	18.2	12.6

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

^a SEER 12 areas.

^b NCHS public use data file for the total US.

^c SEER 9 areas.

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-6
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Blacks

Site	Incidence ^a (1997-2001)			US Mortality ^b (1997-2001)			Survival ^c (1995-2000)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	515.8	689.2	400.1	252.5	347.3	196.5	55.2	57.5	52.7
Oral Cavity & Pharynx:	11.9	19.5	6.2	4.3	7.5	2.0	39.0	33.7	52.1
Lip	0.2	-	-	-	-	-	-	-	-
Tongue	2.7	4.5	1.4	0.8	1.5	0.4	38.5	34.4	47.6
Salivary gland	0.9	1.2	0.8	0.2	0.3	0.1	75.7	64.6	85.5
Floor of mouth	1.1	2.0	0.5	0.1	0.2	0.1	40.0	31.6	57.8
Gum & other oral cavity	2.0	2.9	1.3	0.6	0.9	0.4	42.7	31.7	61.1
Nasopharynx	0.6	1.0	0.4	0.3	0.5	0.2	40.5	45.3	-
Tonsil	1.9	3.5	0.7	0.4	0.7	0.1	37.2	35.4	43.1
Oropharynx	0.6	1.2	-	0.4	0.8	0.2	29.7	32.7	-
Hypopharynx	1.3	2.5	0.5	0.3	0.5	0.1	15.1	14.9	16.6
Other oral cavity & pharynx	0.5	0.9	-	1.1	2.1	0.4	15.9	15.6	-
Digestive System:	114.3	140.4	96.1	67.1	87.4	53.3	36.0	33.1	38.9
Esophagus	6.7	10.6	3.8	6.7	11.7	3.2	8.9	8.5	9.8
Stomach	13.6	18.8	9.9	9.1	13.3	6.3	24.2	21.4	27.5
Small intestine	3.1	3.8	2.7	0.6	0.7	0.5	46.5	42.8	50.0
Colon & Rectum:	63.0	72.9	56.5	28.3	34.3	24.5	54.6	55.5	54.0
Colon	48.7	55.2	44.6	24.8	29.7	21.8	54.4	56.3	53.0
Rectum	14.3	17.7	11.9	3.5	4.6	2.7	55.2	53.5	57.2
Anus, anal canal & anorectum	1.6	1.8	1.4	0.2	0.2	0.2	58.2	52.4	64.0
Liver & Intrahep:	7.2	11.8	3.9	6.1	9.3	3.8	5.4	5.7	5.1
Liver	6.6	10.8	3.5	5.3	8.3	3.1	5.4	5.8	5.3
Intrahep bile duct	0.6	0.9	0.4	0.8	1.0	0.7	0.0	0.0	-
Gallbladder	1.2	0.7	1.5	0.8	0.6	1.0	13.7	5.4	15.2
Other biliary	1.3	1.6	1.1	0.5	0.5	0.4	20.5	8.8	28.5
Pancreas	15.4	17.1	13.9	14.2	16.0	12.8	3.8	2.7	4.8
Retroperitoneum	0.4	0.4	0.4	0.1	0.1	0.1	41.9	-	37.3
Peritoneum, omentum & mesentery	0.4	-	0.6	0.1	0.1	0.2	48.8	-	46.1
Other digestive system	0.5	0.6	0.5	0.4	0.5	0.3	0.0	-	0.0
Respiratory System:	87.8	131.6	57.9	68.3	110.2	41.0	16.6	16.0	17.6
Nose, nasal cavity & middle ear	0.7	0.9	0.6	0.2	0.3	0.1	34.2	27.1	44.5
Larynx	6.4	12.1	2.4	2.7	5.4	0.9	51.0	52.5	46.5
Lung & bronchus	79.8	117.2	54.5	65.2	104.1	39.9	13.2	11.9	15.4
Pleura	0.6	1.0	-	0.1	0.1	-	9.8	3.2	-
Trachea & other respiratory organs	0.3	0.4	-	0.1	0.2	0.1	22.6	22.1	-
Bones & joints	0.7	0.8	0.6	0.4	0.6	0.3	65.6	65.9	64.7
Soft tissue (incl heart)	3.1	3.7	2.6	1.6	1.7	1.6	60.2	57.6	63.0
Skin (ex basal & squam):	3.9	6.1	2.1	1.1	1.6	0.7	56.3	49.4	78.8
Melanoma of the skin	1.0	1.5	0.7	0.5	0.5	0.5	74.0	72.2	75.7
Other non-epithelial skin	2.9	4.6	1.4	0.6	1.1	0.3	52.7	46.6	80.7
Breast	69.2	1.9	119.9	21.0	0.6	35.4	75.1	54.5	75.2
Breast (<i>in situ</i>)	15.6	-	27.4	-	-	-	100.0	-	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

^a SEER 12 areas.

^b NCHS public use data file for the total US.

^c SEER 9 areas.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-6 - continued
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Incidence ^a (1997-2001)			US Mortality ^b (1997-2001)			Survival ^c (1995-2000)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	25.1	-	43.5	12.5	-	21.0	58.5	-	58.5
Cervix uteri	6.7	-	11.8	3.2	-	5.6	65.7	-	65.7
Corpus uteri	10.1	-	17.5	1.9	-	3.1	64.9	-	64.9
Uterus, NOS	0.4	-	0.7	2.3	-	3.8	24.1	-	24.1
Ovary	5.8	-	10.1	4.5	-	7.5	37.9	-	37.9
Vagina	0.6	-	1.1	0.2	-	0.4	50.3	-	50.3
Vulva	1.0	-	1.7	0.2	-	0.3	65.2	-	65.2
Other female genital system	0.4	-	0.6	0.2	-	0.3	68.9	-	68.9
Male Genital System:	112.5	274.0	-	24.7	70.9	-	95.8	95.8	-
Prostate	111.3	271.3	-	24.5	70.4	-	96.0	96.0	-
Testis	0.7	1.5	-	0.1	0.2	-	87.3	87.3	-
Penis	0.3	0.9	-	0.1	0.3	-	66.9	66.9	-
Other male genital system	0.1	0.3	-	0.0	0.1	-	-	-	-
Urinary System:	26.8	40.5	17.7	8.3	12.1	5.9	62.5	65.4	58.4
Urinary bladder	12.6	20.4	7.7	3.9	5.6	2.9	61.9	67.7	51.9
Kidney & renal pelvis	13.3	18.8	9.4	4.2	6.3	2.7	63.5	63.5	63.5
Ureter	0.3	-	-	0.1	-	0.1	-	-	-
Other urinary system	0.6	0.9	0.4	0.1	0.1	0.2	52.6	73.6	-
Eye & Orbit	0.2	-	-	0.0	-	0.0	83.5	-	-
Brain & Nervous System: ^d	4.0	4.6	3.4	2.7	3.3	2.3	37.7	38.3	36.8
Brain	3.5	4.2	3.0	-	-	-	36.6	37.1	35.9
Cranial nerves & other nervous system	0.4	0.4	0.5	-	-	-	47.3	-	42.7
Endocrine System:	4.7	2.8	6.3	0.8	0.7	0.9	89.2	83.0	90.9
Thyroid	4.1	2.2	5.7	0.5	0.4	0.5	95.3	89.1	95.8
Other endocrine & thymus	0.6	0.6	0.6	0.4	0.4	0.3	56.2	69.1	45.0
Lymphoma:	17.0	21.2	13.7	6.2	8.0	4.9	56.6	52.1	62.8
Hodgkin lymphoma	2.4	2.9	2.0	0.4	0.6	0.3	80.4	77.6	83.5
Non-Hodgkin lymphoma	14.6	18.3	11.7	5.7	7.4	4.6	50.5	46.3	56.7
Myeloma	11.0	12.9	9.8	7.5	9.0	6.6	32.1	35.2	29.6
Leukemia:	9.9	12.8	7.9	6.8	9.0	5.4	38.6	39.1	38.1
Lymphocytic:	3.9	5.3	2.9	2.0	2.9	1.4	56.3	55.0	58.4
Acute lymphocytic	0.8	0.9	0.7	0.4	0.5	0.3	54.3	56.0	52.0
Chronic lymphocytic	2.8	4.0	2.0	1.5	2.2	1.1	58.7	54.5	65.2
Other lymphocytic	0.3	-	-	0.1	0.2	0.1	45.5	-	-
Myeloid & Monocytic:	5.3	6.6	4.4	3.0	3.7	2.5	27.0	27.6	26.4
Acute myeloid	3.4	4.1	2.9	2.1	2.5	1.7	24.0	25.0	22.6
Chronic myeloid	1.5	2.1	1.1	0.8	1.0	0.6	33.4	33.2	34.0
Acute monocytic	0.2	-	-	0.0	-	-	-	-	-
Other myeloid & monocytic	0.2	-	-	0.1	0.2	0.1	-	-	-
Other:	0.7	0.9	0.7	1.8	2.4	1.5	16.8	12.7	18.6
Other acute	0.4	0.5	0.3	0.7	0.9	0.6	9.1	-	-
Aleukemic, subleuk & NOS	0.4	-	0.4	1.1	1.5	0.9	22.9	-	-
Ill-defined & unspecified	13.7	16.2	12.0	19.0	24.8	15.2	10.6	12.4	8.9

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

^a SEER 12 areas.

^b NCHS public use data file for the total US.

^c SEER 9 areas.

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-7

MESOTHELIOMAS (Invasive)AGE-ADJUSTED SEER CANCER INCIDENCE RATES^a, 1978-2001

By Race, Sex and Year of Diagnosis

Race/Sex	Year of Diagnosis											
	1978- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1999- 1999	2000- 2001
All Races												
Both Sexes	0.8	0.9	0.9	1.0	1.0	1.1	1.1	1.1	1.2	1.1	1.1	1.0
Males	1.4	1.6	1.6	1.9	1.7	2.0	2.1	2.3	2.2	2.0	2.1	2.0
0-54	0.3	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.3	0.2	0.2	0.1
55-64	3.2	3.7	3.7	4.5	3.5	3.1	4.4	3.7	3.3	4.2	3.7	2.6
65-74	7.0	8.2	7.2	8.6	8.3	11.8	9.6	10.6	10.3	9.0	9.8	9.1
75-84	8.2	10.0	11.7	12.0	12.6	12.7	17.2	16.1	17.8	15.1	16.7	18.7
85+	7.4	4.7	6.1	8.8	7.7	12.8	12.0	20.5	12.4	15.8	15.9	13.6
Females	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
0-54	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1
55-64	0.7	0.9	1.0	0.8	1.0	0.7	0.9	0.9	1.2	0.8	0.5	0.6
65-74	1.4	0.9	2.1	1.4	1.4	1.7	1.4	1.3	1.6	1.5	1.6	1.2
75-84	1.3	1.7	2.0	3.1	2.3	1.7	3.0	2.8	2.6	2.3	2.1	2.8
85+	0.0	1.0	1.2	0.9	1.9	1.8	1.5	2.0	2.1	2.2	1.5	2.7
Whites												
Both Sexes	0.8	0.9	1.0	1.1	1.0	1.1	1.2	1.2	1.2	1.2	1.2	1.1
Males	1.5	1.7	1.7	2.0	1.8	2.2	2.3	2.5	2.3	2.2	2.3	2.2
Females	0.3	0.3	0.5	0.4	0.5	0.4	0.5	0.4	0.5	0.4	0.4	0.4
Blacks												
Both Sexes	0.5	0.3	0.6	0.6	0.6	0.7	0.7	0.7	0.9	0.7	0.6	0.4
Males	0.6	0.7	1.2	1.3	1.0	1.1	1.5	1.3	1.8	1.1	1.3	0.9
Females	0.4	0.0	0.2	0.1	0.3	0.4	0.3	0.3	0.4	0.4	0.2	0.2

^a SEER 9 areas. Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard by 5-year age groups.

Table I-8
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
All Races, 1992-2001

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-0.7 ^c	-1.6 ^c	0.1	-1.0 ^c	-1.5 ^c	-0.7 ^c
Oral Cavity & Pharynx:	-2.0 ^c	-2.4 ^c	-1.4 ^c	-2.6 ^c	-2.8 ^c	-2.5 ^c
Lip	-4.7 ^c	-5.8 ^c	-1.6	-5.2 ^c	-5.6 ^c	-5.7
Tongue	-0.1	-0.5	0.2	-1.9 ^c	-2.3 ^c	-1.5 ^c
Salivary gland	0.6	0.3	0.6	-1.8 ^c	-2.1 ^c	-1.7 ^c
Floor of mouth	-4.8 ^c	-5.1 ^c	-4.1	-9.3 ^c	-9.8 ^c	-8.7 ^c
Gum & other	-3.6 ^c	-4.5 ^c	-2.1 ^c	-3.8 ^c	-4.5 ^c	-3.1 ^c
oral cavity						
Nasopharynx	-1.9 ^c	-2.6 ^c	-0.6	-2.7 ^c	-2.8 ^c	-2.7 ^c
Tonsil	0.8	1.9 ^c	-2.8 ^c	-1.6 ^c	-1.5	-2.5 ^c
Oropharynx	-1.3	-1.7	0.1	-0.5	-0.8	-0.3
Hypopharynx	-3.8 ^c	-4.1 ^c	-3.2	-5.0 ^c	-5.6 ^c	-3.3 ^c
Other oral cavity & pharynx	-6.0 ^c	-6.5 ^c	-5.5 ^c	-2.0 ^c	-1.7 ^c	-3.0 ^c
Digestive System:	-0.4	-0.7 ^c	-0.2	-0.9 ^c	-1.1 ^c	-1.0 ^c
Esophagus	0.3	0.5	-0.9	0.6 ^c	0.7 ^c	0.0
Stomach	-1.6 ^c	-2.3 ^c	-0.9	-2.9 ^c	-3.4 ^c	-2.6 ^c
Small intestine	1.2	0.2	2.2 ^c	-1.0 ^c	-0.7	-1.3 ^c
Colon & Rectum:	-0.8 ^c	-1.1 ^c	-0.5	-1.8 ^c	-2.1 ^c	-1.7 ^c
Colon	-0.9 ^c	-1.3 ^c	-0.5 ^c	-2.0 ^c	-2.3 ^c	-1.8 ^c
Rectum	-0.5	-0.7	-0.5	-0.8 ^c	-0.9 ^c	-0.9 ^c
Anus, anal canal & anorectum	1.7 ^c	2.1	1.5	1.0	0.6	1.3
Liver & Intrahep:	3.4 ^c	3.2 ^c	3.3 ^c	1.9 ^c	2.0 ^c	1.2 ^c
Liver	4.1 ^c	3.8 ^c	4.2 ^c	1.5 ^c	1.8 ^c	0.2
Intrahep bile duct	-0.1	-0.4	-0.1	3.8 ^c	3.2 ^c	4.2 ^c
Gallbladder	-2.0 ^c	-2.2	-1.8 ^c	-2.4 ^c	-1.9 ^c	-2.4 ^c
Other biliary	0.3	0.9	-0.5	-3.0 ^c	-3.1 ^c	-2.9 ^c
Pancreas	-0.5	-0.4	-0.6	-0.1	-0.3 ^c	-0.1
Retroperitoneum	-1.0	1.3	-2.8 ^c	-3.4 ^c	-3.4 ^c	-3.3 ^c
Peritoneum, omentum & mesentery	8.2 ^c	-1.2	10.3 ^c	7.5 ^c	-1.8	10.5 ^c
Other digestive system	2.9 ^c	1.4	4.1 ^c	8.9 ^c	9.3 ^c	8.4 ^c
Respiratory System:	-1.4 ^c	-2.4 ^c	-0.3	-0.9 ^c	-1.9 ^c	0.5 ^c
Nose, nasal cavity & middle ear	-1.3	-2.0	-0.9	-2.2 ^c	-2.4 ^c	-2.5 ^c
Larynx	-2.9 ^c	-3.4 ^c	-1.9	-2.0 ^c	-2.3 ^c	-1.7 ^c
Lung & bronchus	-1.3 ^c	-2.3 ^c	-0.2	-0.8 ^c	-1.9 ^c	0.6 ^c
Pleura	-1.2 ^c	-1.7 ^c	-0.6	-5.8 ^c	-5.9 ^c	-5.9 ^c
Trachea & other respiratory organs	-3.6 ^c	-4.0 ^c	-2.9	-4.4 ^c	-4.7 ^c	-4.1 ^c
Bones & joints	-1.1	-1.3 ^c	-0.7	-0.8 ^c	-0.9 ^c	-0.9
Soft tissue (incl heart)	1.4 ^c	1.9 ^c	0.9	-1.3	-0.9	-1.9 ^c
Skin (ex basal & squam):	-0.2	-1.3 ^c	2.2 ^c	-0.3 ^c	-0.2	-0.6 ^c
Melanoma of the skin	2.5 ^c	2.7 ^c	2.5 ^c	-0.2	0.0	-0.6 ^c
Other non-epithelial skin	-11.0 ^c	-13.3 ^c	0.4	-0.7	-0.9	-0.3
Breast	0.4	1.1	0.6 ^c	-2.5 ^c	0.4	-2.4 ^c
Breast (<i>in situ</i>)	5.8 ^c	6.1	5.9 ^c	-	-	-

^a The APC is the Annual Percent Change over the time interval.
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^c The APC is significantly different from zero (p<.05).

- Statistic could not be calculated.

Table I-8 - continued
 SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
 All Races, 1992-2001

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-1.0 ^c	-	-0.8 ^c	-1.1 ^c	-	-0.9 ^c
Cervix uteri	-2.7 ^c	-	-2.6 ^c	-3.2 ^c	-	-3.0 ^c
Corpus uteri	-0.3	-	-0.1	-1.6 ^c	-	-1.4 ^c
Uterus, NOS	0.7	-	1.2	0.6 ^c	-	1.0 ^c
Ovary	-1.2 ^c	-	-1.0 ^c	-0.8 ^c	-	-0.6 ^c
Vagina	-1.6	-	-1.4	-1.7 ^c	-	-1.3
Vulva	0.5	-	0.9	-0.6	-	-0.3
Other female genital system	-1.3	-	-1.1	3.7	-	3.7
Male Genital System:	-1.7	-2.4 ^c	-	-3.2 ^c	-3.5 ^c	-
Prostate	-1.8	-2.5 ^c	-	-3.2 ^c	-3.6 ^c	-
Testis	1.2 ^c	1.2 ^c	-	-1.1	-1.3	-
Penis	-2.3	-2.5	-	-1.0	-1.4 ^c	-
Other male genital system	0.9	0.6	-	2.9	2.8	-
Urinary System:	0.4 ^c	0.2	0.3 ^c	-0.2 ^c	-0.4 ^c	-0.5 ^c
Urinary bladder	-0.1	-0.1	-0.5 ^c	-0.4 ^c	-0.6 ^c	-0.6 ^c
Kidney & renal pelvis	1.4 ^c	1.3 ^c	1.5 ^c	-0.2	-0.1	-0.4
Ureter	-0.8	-1.8	0.9	-1.8 ^c	-2.2 ^c	-1.2
Other urinary system	-1.3	-0.9	-1.9	6.1 ^c	9.8 ^c	2.7
Eye & Orbit	-2.1 ^c	-2.8	-1.8	-3.3 ^c	-3.6 ^c	-3.3 ^c
Brain & Nervous System: ^d	-0.7	-0.7	-0.6	-0.8 ^c	-0.7 ^c	-1.1 ^c
Brain	-0.7	-0.6	-0.8	-	-	-
Cranial nerves & other nervous system	-0.8	-2.5	0.9	-	-	-
Endocrine System:	3.5 ^c	1.9 ^c	4.1 ^c	0.2	1.1 ^c	-0.4
Thyroid	3.8 ^c	2.4 ^c	4.3 ^c	0.6	2.3 ^c	-0.3
Other endocrine & thymus	0.0	-0.4	0.3	-0.4	-0.3	-0.6
Lymphoma:	-0.1	-0.5	0.6	-0.6	-0.6	-0.6
Hodgkin lymphoma	-0.5	-0.3	-0.8	-3.5 ^c	-4.0 ^c	-2.9 ^c
Non-Hodgkin lymphoma	0.0	-0.5	0.8 ^c	-0.4	-0.3	-0.5
Myeloma	-0.7	-1.0	-0.6	-0.4	-0.6	-0.3
Leukemia:	-1.0 ^c	-1.3 ^c	-0.8 ^c	-0.5 ^c	-0.7 ^c	-0.5 ^c
Lymphocytic:	-1.9 ^c	-2.2 ^c	-1.5 ^c	-1.2 ^c	-1.6 ^c	-1.0 ^c
Acute lymphocytic	0.5	-0.5	1.7	-1.3 ^c	-1.7 ^c	-1.0
Chronic lymphocytic	-2.9 ^c	-2.8 ^c	-3.3 ^c	-0.9 ^c	-1.3 ^c	-0.7
Other lymphocytic	-0.9	-2.2	1.9	-3.7 ^c	-3.7 ^c	-4.1 ^c
Myeloid & Monocytic:	0.4	0.6	0.2	0.5 ^c	0.4	0.5 ^c
Acute myeloid	1.5 ^c	1.7 ^c	1.1	2.0 ^c	1.9 ^c	2.1 ^c
Chronic myeloid	-1.9 ^c	-1.8	-2.1 ^c	-4.8 ^c	-5.1 ^c	-4.8 ^c
Acute monocytic	2.6	3.3	2.1	-7.1 ^c	-5.7 ^c	-8.4 ^c
Other myeloid & monocytic	-1.5	-1.8	-0.4	8.4 ^c	9.6 ^c	6.7 ^c
Other:	-4.4 ^c	-5.9 ^c	-2.6	-1.5 ^c	-1.5 ^c	-1.6 ^c
Other acute	-6.1 ^c	-8.0 ^c	-4.1 ^c	-3.6 ^c	-3.3 ^c	-4.0 ^c
Aleukemic, subleuk & NOS	-2.2 ^c	-3.2 ^c	-0.7	0.8 ^c	0.5	1.0 ^c
Ill-defined & unspecified	-3.4 ^c	-3.6 ^c	-3.3 ^c	0.5	0.6	0.4

^a The APC is the Annual Percent Change over the time interval.
 SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^c The APC is significantly different from zero (p<.05).

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated.

Table I-9
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
Whites, 1992-2001

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-0.5 ^c	-1.5 ^c	0.3	-0.9 ^c	-1.4 ^c	-0.7 ^c
Oral Cavity & Pharynx:	-1.8 ^c	-2.2 ^c	-1.5 ^c	-2.3 ^c	-2.5 ^c	-2.3 ^c
Lip	-4.7 ^c	-5.7 ^c	-1.5	-5.0 ^c	-5.5 ^c	-5.6
Tongue	0.0	-0.1	-0.4	-1.2 ^c	-1.6 ^c	-0.9
Salivary gland	0.9	0.7	0.8	-1.7 ^c	-2.0 ^c	-1.8 ^c
Floor of mouth	-4.4 ^c	-4.6 ^c	-4.0	-9.1 ^c	-9.6 ^c	-8.7 ^c
Gum & other oral cavity	-3.6 ^c	-4.5 ^c	-2.3 ^c	-3.4 ^c	-4.2 ^c	-2.9 ^c
Nasopharynx	-2.6 ^c	-2.8 ^c	-3.1	-3.5 ^c	-3.3 ^c	-4.1 ^c
Tonsil	1.3	2.3 ^c	-2.2	-0.8	-0.7	-2.1 ^c
Oropharynx	-0.8	-1.5	0.8	-0.2	-0.7	0.3
Hypopharynx	-3.1 ^c	-3.6 ^c	-2.4	-4.9 ^c	-5.5 ^c	-3.5 ^c
Other oral cavity & pharynx	-5.7 ^c	-6.6 ^c	-4.4 ^c	-1.7 ^c	-1.5	-2.8 ^c
Digestive System:	-0.3	-0.6 ^c	-0.2	-0.9 ^c	-1.0 ^c	-1.0 ^c
Esophagus	1.5 ^c	1.9 ^c	-0.2	1.6 ^c	1.7 ^c	0.8 ^c
Stomach	-1.8 ^c	-2.3 ^c	-1.3	-3.2 ^c	-3.6 ^c	-2.8 ^c
Small intestine	0.8	0.0	1.5	-1.1 ^c	-0.9	-1.5 ^c
Colon & Rectum:	-0.8 ^c	-1.2 ^c	-0.6	-1.9 ^c	-2.2 ^c	-1.8 ^c
Colon	-0.9 ^c	-1.4 ^c	-0.6 ^c	-2.1 ^c	-2.4 ^c	-2.0 ^c
Rectum	-0.5	-0.7	-0.6	-0.7 ^c	-0.8 ^c	-0.7 ^c
Anus, anal canal & anorectum	2.1 ^c	2.4	1.9	1.5 ^c	1.2	1.8
Liver & Intrahep:	3.7 ^c	3.2 ^c	3.9 ^c	2.0 ^c	2.1 ^c	1.1 ^c
Liver	4.6 ^c	3.9 ^c	5.0 ^c	1.5 ^c	1.9 ^c	-0.1
Intrahep bile duct	0.3	-0.4	0.8	3.8 ^c	3.3 ^c	4.1 ^c
Gallbladder	-1.8 ^c	-1.7	-1.6	-2.6 ^c	-2.1 ^c	-2.5 ^c
Other biliary	0.3	1.1	-0.8	-2.9 ^c	-3.1 ^c	-2.9 ^c
Pancreas	-0.3	0.0	-0.6	0.0	-0.1	0.0
Retroperitoneum	0.0	2.4 ^c	-2.1	-3.4 ^c	-3.9 ^c	-2.8 ^c
Peritoneum, omentum & mesentery	8.4 ^c	-2.3	10.8 ^c	7.7 ^c	-2.1	10.9 ^c
Other digestive system	2.9 ^c	1.5	3.8	8.9 ^c	9.3 ^c	8.4 ^c
Respiratory System:	-1.3 ^c	-2.3 ^c	-0.2	-0.7 ^c	-1.8 ^c	0.6 ^c
Nose, nasal cavity & middle ear	-1.0	-1.8	-0.6	-1.7 ^c	-1.7	-2.3 ^c
Larynx	-2.8 ^c	-3.3 ^c	-1.5	-1.9 ^c	-2.2 ^c	-1.5 ^c
Lung & bronchus	-1.2 ^c	-2.3 ^c	-0.2	-0.7 ^c	-1.7 ^c	0.7 ^c
Pleura	-0.9	-1.5	-0.2	-5.7 ^c	-5.8 ^c	-6.0 ^c
Trachea & other respiratory organs	-3.4 ^c	-3.8 ^c	-3.3	-4.1 ^c	-4.8 ^c	-3.4 ^c
Bones & joints	-0.7	-1.4 ^c	0.3	-0.5 ^c	-0.7 ^c	-0.4
Soft tissue (incl heart)	1.5 ^c	1.6 ^c	1.4	-1.1	-0.9	-1.4
Skin (ex basal & squam):	0.4	-0.8	2.9 ^c	-0.1	0.0	-0.3
Melanoma of the skin	3.1 ^c	3.2 ^c	3.2 ^c	0.0	0.2	-0.4
Other non-epithelial skin	-11.8 ^c	-14.2 ^c	0.7	-0.2	-0.6	0.5
Breast	0.5	1.8	0.8 ^c	-2.7 ^c	0.3	-2.6 ^c
Breast (<i>in situ</i>)	5.7 ^c	7.8 ^c	5.8 ^c	-	-	-

^a The APC is the Annual Percent Change over the time interval.
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^c The APC is significantly different from zero (p<.05).

- Statistic could not be calculated.

Table I-9 - continued
 SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
 Whites, 1992-2001

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-0.8 ^c	-	-0.6 ^c	-0.9 ^c	-	-0.7 ^c
Cervix uteri	-2.3 ^c	-	-2.2 ^c	-2.7 ^c	-	-2.5 ^c
Corpus uteri	-0.4	-	-0.1	-1.6 ^c	-	-1.3 ^c
Uterus, NOS	1.0	-	1.7	0.6	-	0.9 ^c
Ovary	-1.1 ^c	-	-0.8 ^c	-0.7 ^c	-	-0.5 ^c
Vagina	-1.0	-	-0.7	-1.8	-	-1.3
Vulva	1.2	-	1.7 ^c	-0.5	-	-0.2
Other female genital system	-0.8	-	-0.7	4.0	-	4.0
Male Genital System:	-1.7	-2.5 ^c	-	-3.3 ^c	-3.7 ^c	-
Prostate	-1.9	-2.6 ^c	-	-3.3 ^c	-3.7 ^c	-
Testis	1.4 ^c	1.3 ^c	-	-1.2	-1.4	-
Penis	-2.2	-2.6	-	-0.5	-0.8	-
Other male genital system	0.0	-0.4	-	3.0	2.5	-
Urinary System:	0.6 ^c	0.4	0.4 ^c	-0.1	-0.3 ^c	-0.4
Urinary bladder	0.1	0.0	-0.4 ^c	-0.2 ^c	-0.5 ^c	-0.5
Kidney & renal pelvis	1.6 ^c	1.4 ^c	1.4 ^c	-0.2	-0.1	-0.4
Ureter	-0.4	-1.6	1.3	-1.6 ^c	-1.9 ^c	-1.1
Other urinary system	-0.5	-0.7	-0.2	7.5 ^c	11.2 ^c	3.8
Eye & Orbit	-1.8	-2.9	-1.1	-3.4 ^c	-3.6 ^c	-3.6 ^c
Brain & Nervous System: ^d	-0.4	-0.5	-0.3	-0.7 ^c	-0.6 ^c	-1.0 ^c
Brain	-0.3	-0.4	-0.4	-	-	-
Cranial nerves & other nervous system	-1.1	-3.1	0.7	-	-	-
Endocrine System:	3.9 ^c	2.4 ^c	4.6 ^c	0.1	1.2 ^c	-0.6
Thyroid	4.2 ^c	2.8 ^c	4.8 ^c	0.5	2.3 ^c	-0.5
Other endocrine & thymus	0.6	0.1	1.2	-0.4	-0.1	-0.7
Lymphoma:	-0.1	-0.5	0.6	-0.6	-0.5	-0.6
Hodgkin lymphoma	-0.4	-0.3	-0.5	-3.4 ^c	-3.7 ^c	-3.0 ^c
Non-Hodgkin lymphoma	0.0	-0.5	0.8 ^c	-0.4	-0.3	-0.5
Myeloma	-0.5	-0.7	-0.7	-0.3	-0.4	-0.3
Leukemia:	-0.9 ^c	-1.3 ^c	-0.5	-0.4 ^c	-0.6 ^c	-0.4 ^c
Lymphocytic:	-1.7 ^c	-2.1 ^c	-1.2	-1.1 ^c	-1.5 ^c	-1.0 ^c
Acute lymphocytic	0.9	-0.3	2.6 ^c	-1.2 ^c	-1.6 ^c	-0.9
Chronic lymphocytic	-2.7 ^c	-2.7 ^c	-3.2 ^c	-0.8 ^c	-1.2 ^c	-0.7
Other lymphocytic	-1.0	-2.3	2.0	-3.8 ^c	-3.8 ^c	-4.3 ^c
Myeloid & Monocytic:	0.5	0.5	0.4	0.6 ^c	0.5	0.6 ^c
Acute myeloid	1.6 ^c	1.5 ^c	1.4 ^c	2.1 ^c	2.0 ^c	2.2 ^c
Chronic myeloid	-1.9 ^c	-1.9	-2.1 ^c	-4.9 ^c	-5.2 ^c	-4.6 ^c
Acute monocytic	3.4	3.7	3.6	-7.1 ^c	-5.5 ^c	-8.9 ^c
Other myeloid & monocytic	-1.7	-0.9	-2.1	8.6 ^c	9.7 ^c	6.8 ^c
Other:	-4.2 ^c	-6.0 ^c	-2.1	-1.4 ^c	-1.4 ^c	-1.5 ^c
Other acute	-5.9 ^c	-8.0 ^c	-3.3	-3.5 ^c	-3.2 ^c	-4.0 ^c
Aleukemic, subleuk & NOS	-2.0 ^c	-3.4 ^c	-0.5	0.9 ^c	0.5	1.3 ^c
Ill-defined & unspecified	-3.2 ^c	-3.5 ^c	-3.0 ^c	0.7	0.8	0.6

^a The APC is the Annual Percent Change over the time interval.
 SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^c The APC is significantly different from zero (p<.05).

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated.

Table I-10
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
Blacks, 1992-2001

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-1.2 ^c	-1.9 ^c	-0.4	-1.4 ^c	-1.9 ^c	-0.8 ^c
Oral Cavity & Pharynx:	-3.2 ^c	-3.4 ^c	-2.1	-4.2 ^c	-4.4 ^c	-3.3 ^c
Lip	-1.4	-	-	-	-	-
Tongue	-1.8	-3.2	1.4	-6.1 ^c	-6.1 ^c	-6.1 ^c
Salivary gland	-0.8	-0.6	-0.8	-1.2	-3.3	1.7
Floor of mouth	-6.6 ^c	-6.3 ^c	-5.2	-9.9 ^c	-10.1 ^c	-8.8 ^c
Gum & other oral cavity	-4.1 ^c	-5.4 ^c	-1.1	-5.8 ^c	-6.0 ^c	-4.9 ^c
Nasopharynx	-2.0	-2.5	0.1	-1.0	-2.4	2.3
Tonsil	-0.7	0.7	-4.1	-4.3 ^c	-4.5 ^c	-3.4
Oropharynx	-2.0	-1.1	-3.3	-1.7	-1.6	-2.0
Hypopharynx	-6.9 ^c	-6.7 ^c	-6.4 ^c	-6.2 ^c	-7.1 ^c	-2.4
Other oral cavity & pharynx	-6.0 ^c	-4.0	-	-2.8 ^c	-2.7 ^c	-2.9
Digestive System:	-0.7 ^c	-1.0 ^c	-0.3	-1.2 ^c	-1.6 ^c	-0.9 ^c
Esophagus	-5.2 ^c	-5.8 ^c	-4.1 ^c	-4.0 ^c	-4.3 ^c	-3.3 ^c
Stomach	-1.4	-2.6 ^c	0.0	-2.6 ^c	-2.9 ^c	-2.3 ^c
Small intestine	3.6 ^c	2.0	5.8 ^c	-0.3	-0.4	-0.1
Colon & Rectum:	-0.3	-0.6	0.0	-0.7 ^c	-0.8 ^c	-0.7 ^c
Colon	-0.3	-0.5	-0.2	-0.7 ^c	-0.8 ^c	-0.6 ^c
Rectum	-0.3	-0.8	0.4	-1.2 ^c	-0.9 ^c	-1.8 ^c
Anus, anal canal & anorectum	2.5	3.1	1.9	-1.8	-2.3	-2.2
Liver & Intrahep:	3.6 ^c	4.6 ^c	1.9	1.3 ^c	1.1	1.1
Liver	4.0 ^c	4.8 ^c	2.2	0.8	0.8	0.1
Intrahep bile duct	-0.2	2.1	-1.9	4.9 ^c	3.7 ^c	6.1 ^c
Gallbladder	-1.8	-2.6	-1.5	-0.8	-0.1	-1.0
Other biliary	-0.4	-1.3	0.1	-2.0	0.0	-2.6 ^c
Pancreas	-2.2 ^c	-2.0 ^c	-2.5 ^c	-1.1 ^c	-1.6 ^c	-0.7 ^c
Retroperitoneum	-2.7	1.0	-3.4	-5.5	-0.2	-8.7 ^c
Peritoneum, omentum & mesentery	5.6	-	5.5	5.2 ^c	0.2	6.5 ^c
Other digestive system	3.3	-0.8	6.7	8.2 ^c	8.6 ^c	8.4 ^c
Respiratory System:	-1.6 ^c	-2.6 ^c	0.2	-1.6 ^c	-2.5 ^c	0.3
Nose, nasal cavity & middle ear	-3.4	-3.6	-2.8	-5.6 ^c	-7.1 ^c	-4.7
Larynx	-3.1 ^c	-2.9 ^c	-3.4	-2.7 ^c	-2.8 ^c	-2.4 ^c
Lung & bronchus	-1.5 ^c	-2.6 ^c	0.5	-1.5 ^c	-2.4 ^c	0.4
Pleura	-4.7	-4.4	-3.0	-6.7 ^c	-7.3 ^c	-3.9
Trachea & other respiratory organs	3.3	8.8	-	-7.2 ^c	-4.4 ^c	-11.1 ^c
Bones & joints	-2.4	-1.8	-4.0	-3.2	-3.6 ^c	-3.5
Soft tissue (incl heart)	0.9	2.4	0.0	-2.9 ^c	0.3	-4.7 ^c
Skin (ex basal & squam):	-6.8 ^c	-8.1 ^c	-0.8	-3.8 ^c	-4.0 ^c	-3.5
Melanoma of the skin	-0.7	2.2	-3.4	-0.8	-0.7	-0.7
Other non-epithelial skin	-8.4 ^c	-10.4 ^c	0.7	-5.8 ^c	-5.2 ^c	-7.2 ^c
Breast	-0.3	4.2	-0.3	-1.1 ^c	1.0	-1.2 ^c
Breast (<i>in situ</i>)	6.5 ^c	-	6.5 ^c	-	-	-

^a The APC is the Annual Percent Change over the time interval.
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^c The APC is significantly different from zero (p<.05).

- Statistic could not be calculated.

Table I-10 - continued
 SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
 Blacks, 1992-2001

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-1.2 ^c	-	-1.1 ^c	-1.9 ^c	-	-1.9 ^c
Cervix uteri	-3.1 ^c	-	-3.1 ^c	-5.1 ^c	-	-5.1 ^c
Corpus uteri	0.9	-	1.0	-1.4 ^c	-	-1.4 ^c
Uterus, NOS	-0.7	-	-0.7	1.0	-	1.1
Ovary	-1.6	-	-1.6	-1.0 ^c	-	-0.9 ^c
Vagina	-2.6	-	-2.4	-2.1	-	-2.2
Vulva	-1.7	-	-1.5	-0.9	-	-0.9
Other female genital system	-4.6	-	-4.0	2.1	-	2.1
Male Genital System:	-1.7 ^c	-2.2 ^c	-	-2.5 ^c	-2.3 ^c	-
Prostate	-1.7 ^c	-2.3 ^c	-	-2.5 ^c	-2.3 ^c	-
Testis	6.2 ^c	6.4 ^c	-	2.2	2.3	-
Penis	-4.0	-2.7	-	-5.5 ^c	-6.3 ^c	-
Other male genital system	-	-	-	4.0	5.9	-
Urinary System:	0.9	0.7	1.5	-0.7 ^c	-0.9 ^c	-0.6
Urinary bladder	-0.2	-0.3	0.3	-1.6 ^c	-2.2 ^c	-1.0
Kidney & renal pelvis	2.2 ^c	1.9	2.8 ^c	0.2	0.5	-0.1
Ureter	-0.3	2.0	1.9	-5.5 ^c	-10.1 ^c	-2.0
Other urinary system	-2.8 ^c	-1.3	-3.5	-1.7	-1.2	-2.1
Eye & Orbit	-5.2	-3.9	-4.9	2.4	5.9	1.3
Brain & Nervous System: ^d	-0.6	0.1	-0.9	-0.6	-0.8 ^c	-0.5
Brain	-0.6	0.1	-1.4	-	-	-
Cranial nerves & other nervous system	0.5	1.0	1.3	-	-	-
Endocrine System:	2.1 ^c	0.1	2.7 ^c	0.9	0.7	1.2
Thyroid	3.2 ^c	0.8	3.8 ^c	2.5 ^c	4.0 ^c	2.0
Other endocrine & thymus	-3.9	-2.8	-4.7	-1.0	-2.0 ^c	0.1
Lymphoma:	0.1	-1.2	1.9	-0.7	-0.7	-0.4
Hodgkin lymphoma	-0.8	1.2	-3.1	-4.5 ^c	-5.5 ^c	-3.3 ^c
Non-Hodgkin lymphoma	0.2	-1.5	2.9 ^c	-0.3	-0.3	-0.2
Myeloma	-1.7 ^c	-1.7	-1.6	-0.5	-1.0 ^c	-0.1
Leukemia:	-0.9	-1.2	-0.5	-1.0 ^c	-1.1 ^c	-0.8 ^c
Lymphocytic:	-3.1 ^c	-3.8	-1.7	-1.8 ^c	-2.4 ^c	-0.8
Acute lymphocytic	-0.9	-2.3	0.1	-2.3	-2.8	-1.7
Chronic lymphocytic	-4.0 ^c	-4.1	-3.2	-1.7 ^c	-2.4 ^c	-0.4
Other lymphocytic	0.9	-3.5	-	-1.6	-1.0	-2.3
Myeloid & Monocytic:	1.6	2.4 ^c	0.6	-0.1	0.0	-0.3
Acute myeloid	3.7 ^c	5.8 ^c	1.5	1.9 ^c	2.0 ^c	1.7 ^c
Chronic myeloid	-2.6	-2.7	-2.8	-5.2 ^c	-5.0 ^c	-5.4 ^c
Acute monocytic	1.1	-	-	-9.2	-	-3.1
Other myeloid & monocytic	4.8	-	9.7 ^c	8.0 ^c	8.5	5.9 ^c
Other:	-4.6	-8.2	-1.8	-1.5 ^c	-1.1	-1.6
Other acute	-3.4	-5.5	-4.8	-3.8 ^c	-3.4 ^c	-3.8
Aleukemic, subleuk & NOS	-5.7	-11.7	1.6	0.2	0.4	0.1
Ill-defined & unspecified	-4.3 ^c	-4.0 ^c	-4.5 ^c	-0.6	-0.4	-0.7

^a The APC is the Annual Percent Change over the time interval.
 SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^c The APC is significantly different from zero (p<.05).

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated.

Table I-11

AGE DISTRIBUTION (%) OF INCIDENCE CASES BY SITE, 1997-2001

All Races, Both Sexes

Site	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	1.1	2.9	6.3	13.2	19.7	27.0	22.5	7.3	100.0%	816,932
Oral cavity & Pharynx	0.6	2.9	7.8	19.6	22.3	24.1	17.3	5.5	100.0%	18,668
Esophagus	0.0	0.5	2.7	12.1	21.8	31.1	24.2	7.6	100.0%	7,772
Stomach	0.1	1.6	4.6	10.2	15.8	26.7	28.2	12.8	100.0%	15,274
Colon & Rectum	0.1	1.0	3.4	9.9	16.8	27.0	29.3	12.6	100.0%	91,850
Males	0.1	1.0	3.6	10.8	19.2	29.2	27.5	8.7	100.0%	46,176
Females	0.0	0.9	3.2	9.0	14.4	24.7	31.1	16.5	100.0%	45,674
Colon	0.1	0.8	2.9	8.4	15.4	27.0	31.3	14.1	100.0%	66,251
Rectum	0.1	1.4	4.7	13.7	20.4	26.8	24.2	8.7	100.0%	25,599
Liver & Intrahep	1.3	1.3	4.4	17.1	20.4	26.8	21.9	6.9	100.0%	10,395
Pancreas	0.1	0.4	2.7	9.7	17.0	28.3	29.6	12.1	100.0%	18,790
Larynx	0.0	0.4	4.0	15.0	27.1	31.6	18.2	3.8	100.0%	6,510
Lung & Bronchus	0.0	0.3	2.2	8.9	20.7	34.0	27.4	6.5	100.0%	105,298
Males	0.0	0.2	2.1	8.9	21.4	34.7	26.9	5.8	100.0%	58,192
Females	0.0	0.3	2.3	8.8	19.9	33.1	28.1	7.4	100.0%	47,106
Melanoma of the skin	0.8	9.4	15.3	19.6	17.4	18.4	14.4	4.8	100.0%	30,483
Breast(females)	0.0	2.0	10.8	22.0	21.5	21.2	16.9	5.6	100.0%	128,968
Breast(females, <i>in situ</i>)	0.0	1.0	11.9	28.5	23.4	20.4	12.8	2.1	100.0%	28,270
Cervix uteri	0.2	16.0	27.0	22.3	13.9	10.9	7.0	2.8	100.0%	8,983
Corpus & Uterus, NOS	0.0	1.5	6.4	18.4	25.4	24.8	18.3	5.3	100.0%	23,279
Ovary	1.2	3.4	8.2	19.3	20.7	21.6	19.0	6.6	100.0%	13,348
Prostate	0.0	0.0	0.5	7.6	25.1	38.5	23.5	4.8	100.0%	127,779
Testis	5.5	46.6	31.6	12.1	2.6	0.9	0.6	0.1	100.0%	5,277
Urinary bladder	0.1	0.6	2.5	8.1	16.5	29.8	31.4	10.9	100.0%	34,766
Kidney & Renal pelvis	2.0	1.4	6.4	15.6	22.3	26.6	20.2	5.6	100.0%	19,693
Brain & Other nervous	13.5	9.8	11.5	14.4	15.3	17.5	14.5	3.6	100.0%	11,565
Thyroid	2.3	20.7	23.3	21.8	14.3	9.9	6.2	1.5	100.0%	13,502
Hodgkin lymphoma	12.7	33.8	18.8	11.6	8.1	7.7	5.7	1.7	100.0%	5,101
Non-Hodgkin lymphoma	1.7	5.1	9.0	13.8	16.7	23.3	22.7	7.7	100.0%	33,470
Myeloma	0.0	0.6	3.3	11.3	18.7	28.6	28.4	9.1	100.0%	9,539
Leukemia	11.3	5.3	6.0	9.7	13.6	21.1	23.0	10.1	100.0%	21,418
Acute lymphocytic	63.9	9.4	6.0	5.8	5.0	4.7	3.7	1.6	100.0%	2,903
Chronic lymphocytic	0.0	0.2	2.4	9.5	18.4	27.9	29.1	12.5	100.0%	6,034
Acute myeloid	6.1	7.3	7.2	9.9	13.4	23.1	24.5	8.5	100.0%	6,648
Chronic myeloid	2.2	8.8	10.4	12.7	13.5	20.3	22.1	10.1	100.0%	2,909
All other leukemia	3.4	3.6	6.5	10.4	12.8	19.4	27.2	16.8	100.0%	2,924

Source: SEER 12 areas.

Table I-12
MEDIAN AGE OF CANCER PATIENTS AT DIAGNOSIS^a, 1997-2001
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	67.0	68.0	66.0	68.0	68.0	67.0	64.0	65.0	63.0
Oral Cavity & Pharynx:	63.0	62.0	67.0	64.0	63.0	69.0	57.0	57.0	57.0
Lip	70.0	68.0	74.0	70.0	69.0	75.0	56.5	42.5	61.5
Tongue	62.0	60.0	65.0	62.0	61.0	66.0	57.0	56.5	58.0
Salivary gland	63.0	65.0	61.0	65.0	66.0	63.0	56.0	56.5	51.5
Floor of mouth	64.0	62.0	67.0	64.0	62.0	68.0	56.0	56.0	57.0
Gum & other oral cavity	67.0	64.0	71.0	69.0	65.0	73.0	57.0	57.0	56.0
Nasopharynx	53.0	52.0	54.0	58.0	57.0	64.0	47.0	48.0	46.0
Tonsil	58.0	57.0	62.0	58.0	57.0	63.0	56.0	57.0	55.0
Oropharynx	64.0	62.0	68.0	65.0	63.0	69.0	60.0	59.0	64.0
Hypopharynx	66.0	65.0	68.0	67.0	66.0	69.0	59.5	59.5	59.5
Other oral cavity & pharynx	66.0	65.0	69.0	66.0	65.0	70.0	64.0	62.5	67.0
Digestive System:	71.0	69.0	73.0	72.0	70.0	74.0	67.0	65.0	69.0
Esophagus	69.0	68.0	73.0	70.0	68.0	74.0	64.0	63.0	66.0
Stomach	72.0	70.0	74.0	72.0	71.0	75.0	70.0	67.0	73.0
Small intestine	67.0	66.0	69.0	68.0	67.0	70.0	64.0	63.5	65.0
Colon & Rectum:	72.0	70.0	74.0	73.0	71.0	75.0	67.0	66.0	69.0
Colon	73.0	71.0	75.0	74.0	72.0	76.0	69.0	67.0	70.0
Rectum	68.0	67.0	70.0	69.0	68.0	71.0	64.0	63.0	64.0
Anus, anal canal & anorectum	61.0	57.0	65.0	63.0	58.0	66.0	52.0	50.0	56.0
Liver & Intrahep:	67.0	64.0	71.0	69.0	66.0	73.0	61.0	58.0	67.0
Liver	66.0	64.0	70.0	68.0	66.0	72.0	60.0	58.0	67.0
Intrahep bile duct	73.0	71.0	76.0	73.0	71.0	76.0	68.0	69.0	67.0
Gallbladder	73.0	73.0	73.0	73.0	74.0	73.0	70.0	70.0	69.0
Other biliary	73.0	71.0	74.0	73.0	72.0	75.0	70.0	67.0	74.0
Pancreas	72.0	70.0	74.0	73.0	70.0	75.0	68.0	65.0	71.0
Retroperitoneum	60.0	60.0	60.5	61.0	60.0	61.0	55.0	55.0	56.5
Peritoneum, omentum & mesentery	67.0	65.0	68.0	68.0	65.0	68.0	66.0	66.0	66.0
Other digestive system	73.5	71.0	76.0	74.0	72.0	76.0	70.5	66.5	72.0
Respiratory System:	70.0	70.0	70.0	70.0	70.0	71.0	66.0	65.0	66.0
Nose, nasal cavity & middle ear	65.0	62.0	68.0	65.0	63.0	68.0	63.0	62.0	64.0
Larynx	66.0	66.0	65.0	66.0	66.0	66.0	62.0	62.0	61.0
Lung & bronchus	70.0	70.0	71.0	71.0	70.0	71.0	66.0	66.0	67.0
Pleura	73.0	74.0	73.0	74.0	74.0	73.0	68.0	71.0	66.0
Trachea & other respiratory organs	45.0	40.0	57.0	42.0	38.0	53.0	55.0	51.0	70.0
Bones & joints	38.0	34.0	42.0	39.0	35.0	43.5	32.0	32.0	32.0
Soft tissue (incl heart)	56.0	55.0	56.0	57.0	57.0	57.0	48.0	43.5	53.0
Skin (ex basal & squam):	57.0	60.0	54.0	58.0	60.0	54.0	42.0	41.0	48.0
Melanoma of the skin	57.0	60.0	53.0	57.0	61.0	53.0	59.0	63.0	52.0
Other non-epithelial skin	57.0	51.0	67.0	63.0	57.0	70.0	40.0	39.0	47.5
Breast	61.0	67.0	61.0	63.0	68.0	63.0	57.0	61.0	57.0
Breast (<i>in situ</i>) ^b	-	-	58.0	-	-	58.0	-	-	57.0

^a SEER 12 areas.
^b Females only.
 - Statistic could not be calculated.

Table I-12 - continued
MEDIAN AGE OF CANCER PATIENTS AT DIAGNOSIS^a, 1997-2001
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	61.0	-	61.0	62.0	-	62.0	60.0	-	60.0
Cervix uteri	47.0	-	47.0	46.0	-	46.0	49.0	-	49.0
Corpus uteri	64.0	-	64.0	65.0	-	65.0	64.0	-	64.0
Uterus, NOS	69.0	-	69.0	70.0	-	70.0	62.0	-	62.0
Ovary	63.0	-	63.0	64.0	-	64.0	62.0	-	62.0
Vagina	69.0	-	69.0	69.0	-	69.0	65.5	-	65.5
Vulva	70.0	-	70.0	71.0	-	71.0	55.0	-	55.0
Other female genital system	62.0	-	62.0	64.0	-	64.0	48.0	-	48.0
Male Genital System:	68.0	68.0	-	69.0	69.0	-	66.0	66.0	-
Prostate	69.0	69.0	-	69.0	69.0	-	66.0	66.0	-
Testis	34.0	34.0	-	34.0	34.0	-	35.0	35.0	-
Penis	68.5	68.5	-	68.0	68.0	-	70.0	70.0	-
Other male genital system	68.0	68.0	-	68.0	68.0	-	45.0	45.0	-
Urinary System:	70.0	70.0	71.0	71.0	70.0	71.0	66.0	65.0	67.0
Urinary bladder	72.0	72.0	74.0	72.0	72.0	74.0	71.0	70.0	73.0
Kidney & renal pelvis	65.0	65.0	67.0	66.0	65.0	68.0	61.0	61.0	62.0
Ureter	74.0	72.0	75.5	74.0	72.0	76.0	73.0	75.0	72.0
Other urinary system	72.0	73.0	72.0	73.0	73.0	73.0	66.0	69.0	64.0
Eye & Orbit	58.0	57.0	60.5	60.0	58.0	62.0	2.0	2.0	2.5
Brain & Nervous System:	55.0	54.0	56.0	56.0	55.0	58.0	47.0	46.0	49.0
Brain	56.0	54.0	57.0	57.0	55.0	58.0	47.0	46.0	49.5
Cranial nerves & other nervous system	49.0	47.0	50.0	49.0	47.0	50.0	48.0	45.0	48.0
Endocrine System:	46.0	50.0	45.0	46.0	50.0	44.0	48.0	51.0	47.5
Thyroid	46.0	51.0	45.0	46.0	51.0	44.0	48.0	52.0	47.0
Other endocrine & thymus	48.0	46.0	50.0	48.0	46.5	51.0	49.0	47.0	49.0
Lymphomas:	64.0	61.0	67.0	65.0	62.0	68.0	51.0	49.0	54.0
Hodgkin lymphoma	36.0	38.0	34.0	37.0	38.0	35.0	33.0	35.0	31.0
Non-Hodgkin lymphoma	66.0	64.0	69.0	67.0	65.0	70.0	55.0	52.0	59.0
Myeloma	71.0	69.0	72.0	71.0	70.0	73.0	68.0	66.5	69.0
Leukemia:	67.0	66.0	68.0	68.0	67.0	69.0	60.0	59.0	62.0
Lymphocytic:	64.0	63.0	66.0	65.0	64.0	68.0	60.0	60.0	62.0
Acute lymphocytic	11.0	11.0	10.0	10.0	11.0	10.0	13.0	13.0	13.0
Chronic lymphocytic	72.0	70.0	74.0	73.0	71.0	75.0	69.0	67.0	71.0
Other lymphocytic	63.0	61.0	68.0	63.0	61.0	69.5	62.0	63.0	58.0
Myeloid & Monocytic:	67.0	67.0	68.0	69.0	68.0	69.0	60.0	59.0	62.0
Acute myeloid	68.0	68.0	68.0	69.0	68.0	69.0	63.0	61.0	65.0
Chronic myeloid	66.0	66.0	67.0	68.0	68.0	69.0	55.0	55.5	55.0
Acute monocytic	62.0	63.5	60.0	63.0	66.0	61.0	60.0	57.5	60.0
Other myeloid & monocytic	74.0	73.0	75.0	75.0	73.5	76.0	72.0	72.0	71.5
Other:	77.0	76.0	78.0	78.0	76.0	79.0	68.0	68.0	67.5
Other acute	76.0	75.0	77.0	77.0	76.0	78.0	69.0	68.0	72.0
Aleukemic, subleuk & NOS	78.0	76.0	79.0	78.0	77.0	80.0	59.0	67.0	58.0
Ill-defined & unspecified	73.0	71.0	75.0	74.0	72.0	76.0	67.0	64.0	70.0

^a SEER 12 areas.
 - Statistic could not be calculated.

Table I-13

AGE DISTRIBUTION (%) OF DEATHS BY SITE, 1997-2001

All Races, Both Sexes

Site	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	0.4	0.9	3.1	8.6	16.1	27.8	29.5	13.5	100.0%	2,737,842
Oral cavity & Pharynx	0.2	0.9	3.9	13.8	21.8	26.5	22.3	10.6	100.0%	38,537
Esophagus	0.0	0.3	2.3	10.9	21.1	31.0	25.4	8.9	100.0%	59,719
Stomach	0.0	1.1	3.8	8.6	14.3	25.1	30.6	16.6	100.0%	63,693
Colon & Rectum	0.0	0.6	2.3	7.1	13.8	25.2	31.4	19.7	100.0%	285,131
Males	0.0	0.6	2.5	8.1	16.2	28.6	30.7	13.4	100.0%	141,124
Females	0.0	0.5	2.1	6.2	11.4	21.9	32.0	25.8	100.0%	144,007
Colon	0.0	0.5	2.1	6.7	13.3	25.1	32.0	20.2	100.0%	243,813
Rectum	0.0	0.8	3.3	9.6	16.4	26.0	27.7	16.2	100.0%	41,318
Liver & Intrahep	0.5	0.8	3.3	12.3	17.1	27.6	27.7	10.7	100.0%	62,967
Pancreas	0.0	0.2	2.0	7.8	16.0	28.3	31.4	14.3	100.0%	144,224
Larynx	0.0	0.1	2.0	10.9	23.7	32.0	24.1	7.1	100.0%	19,149
Lung & Bronchus	0.0	0.1	1.8	7.6	19.2	34.3	29.0	8.0	100.0%	771,127
Males	0.0	0.1	1.7	7.7	19.9	35.3	28.3	7.0	100.0%	452,846
Females	0.0	0.2	1.9	7.4	18.2	32.9	30.0	9.5	100.0%	318,281
Melanoma of the skin	0.2	3.2	8.7	15.5	17.3	22.8	22.2	10.0	100.0%	36,846
Breast(females)	0.0	1.2	6.9	15.3	17.8	21.9	22.8	14.0	100.0%	208,089
Cervix uteri	0.0	6.0	17.1	22.2	17.4	16.0	13.8	7.5	100.0%	21,335
Corpus & Uterus, NOS	0.0	0.5	2.0	7.2	16.0	27.9	30.4	16.0	100.0%	32,445
Ovary	0.1	0.8	3.5	11.1	17.5	26.7	28.5	11.9	100.0%	68,998
Prostate	0.0	0.0	0.1	1.2	6.3	22.9	42.3	27.2	100.0%	158,617
Testis	2.3	34.0	29.6	15.1	7.0	5.5	4.8	1.7	100.0%	1,737
Urinary bladder	0.0	0.1	0.9	3.8	10.1	24.2	36.8	24.1	100.0%	59,476
Kidney & Renal pelvis	0.5	0.6	3.0	10.6	18.8	27.7	27.2	11.6	100.0%	57,708
Brain & Other nervous	4.3	4.3	8.4	14.7	18.9	24.4	19.6	5.3	100.0%	63,169
Thyroid	0.2	1.0	2.7	7.8	15.6	25.4	31.5	15.7	100.0%	6,328
Hodgkin lymphoma	2.4	16.6	13.1	12.2	11.6	18.1	19.0	7.0	100.0%	6,767
Non-Hodgkin lymphoma	0.5	2.0	3.8	7.9	13.8	25.3	32.5	14.2	100.0%	114,847
Myeloma	0.0	0.1	1.4	6.3	14.9	29.5	34.1	13.6	100.0%	52,520
Leukemia	3.4	3.5	4.0	6.7	11.7	23.9	30.8	16.0	100.0%	104,953
Acute lymphocytic	22.4	15.6	9.1	10.2	10.7	13.3	12.9	5.7	100.0%	6,989
Chronic lymphocytic	0.0	0.1	0.6	3.0	9.7	25.0	36.2	25.5	100.0%	21,511
Acute myeloid	3.0	3.9	4.9	8.5	13.8	26.5	29.2	10.1	100.0%	35,163
Chronic myeloid	1.3	5.0	7.9	11.4	14.6	22.4	25.4	12.2	100.0%	9,880
All other leukemia	2.5	2.4	2.9	5.0	10.1	23.0	34.4	19.7	100.0%	31,410

Source: NCHS public use data file for the total US.

Table I-14
MEDIAN AGE OF CANCER PATIENTS AT DEATH^a, 1997-2001
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	72.0	72.0	73.0	73.0	72.0	74.0	69.0	68.0	69.0
Oral Cavity & Pharynx:	68.0	66.0	73.0	70.0	67.0	75.0	61.0	60.0	65.0
Lip	76.0	73.0	83.0	76.0	73.0	83.0	72.0	58.0	81.0
Tongue	67.0	65.0	73.0	68.0	66.0	74.0	60.0	59.0	62.0
Salivary gland	74.0	73.0	75.0	74.0	73.0	76.0	65.0	63.0	66.0
Floor of mouth	67.0	64.0	71.0	68.0	65.0	72.0	59.0	56.0	61.5
Gum & other oral cavity	73.0	68.0	78.0	74.0	69.0	79.0	64.0	61.0	69.0
Nasopharynx	63.0	61.0	67.0	66.0	64.0	69.0	56.0	54.0	60.0
Tonsil	63.0	62.0	69.0	65.0	62.0	70.0	59.0	59.0	59.5
Oropharynx	67.0	65.0	73.0	69.0	67.0	74.0	59.0	58.0	65.0
Hypopharynx	66.0	66.0	69.0	68.0	67.0	71.0	60.0	60.0	63.5
Other oral cavity & pharynx	69.0	67.0	72.0	70.0	69.0	73.0	63.0	62.0	66.0
Digestive System:	73.0	71.0	76.0	74.0	72.0	77.0	69.0	67.0	72.0
Esophagus	70.0	68.0	74.0	71.0	69.0	75.0	65.0	64.0	68.0
Stomach	74.0	72.0	76.0	74.0	72.0	77.0	71.0	69.0	75.0
Small intestine	72.0	70.0	73.0	72.0	71.0	74.0	66.0	63.0	67.0
Colon & Rectum	75.0	73.0	77.0	75.0	73.0	78.0	71.0	69.0	73.0
Anus, anal canal & anorectum	68.0	64.0	70.0	68.0	65.0	70.0	62.0	57.0	68.0
Liver & Intrahep:	71.0	68.0	74.0	72.0	70.0	75.0	64.0	61.0	70.0
Liver	70.0	68.0	74.0	71.0	69.0	75.0	64.0	60.0	71.0
Intrahep bile duct	73.0	72.0	75.0	74.0	72.0	75.0	69.0	68.0	70.0
Gallbladder	74.0	74.0	75.0	75.0	74.0	75.0	71.0	71.0	70.0
Other biliary	76.0	75.0	78.0	77.0	75.0	78.0	72.0	71.0	73.0
Pancreas	73.0	71.0	75.0	74.0	71.0	76.0	70.0	67.0	73.0
Retroperitoneum	71.0	69.0	72.0	72.0	70.0	73.0	60.0	60.0	61.5
Peritoneum, omentum & mesentery	71.0	68.0	71.0	71.0	69.0	71.0	67.0	62.5	69.0
Other digestive system	77.0	74.0	80.0	78.0	74.0	81.0	72.0	68.0	77.0
Respiratory System:	71.0	71.0	72.0	71.0	71.0	72.0	67.0	67.0	68.0
Nose, nasal cavity & middle ear	70.0	67.0	74.0	71.0	69.0	75.0	62.0	59.5	66.0
Larynx	69.0	68.0	70.0	70.0	70.0	71.0	64.0	63.5	66.0
Lung & bronchus	71.0	71.0	72.0	71.0	71.0	72.0	68.0	67.0	68.0
Pleura	74.0	73.0	76.0	74.0	74.0	76.0	70.0	70.0	71.5
Trachea & other respiratory organs	68.0	65.0	72.5	69.0	66.0	73.0	64.0	62.0	69.5
Bones & joints	60.0	55.0	65.0	62.0	57.0	68.0	48.0	46.0	55.0
Soft tissue (incl heart)	65.0	64.0	67.0	67.0	65.0	68.0	57.0	52.0	59.0
Skin (ex basal & squam):	69.0	68.0	71.0	69.0	68.0	71.0	64.0	62.0	71.0
Melanoma of the skin	67.0	66.0	68.0	67.0	66.0	68.0	71.0	66.0	73.0
Other non-epithelial skin	75.0	72.0	80.0	76.0	73.0	80.0	62.0	59.0	67.0
Breast	69.0	71.0	69.0	70.0	72.0	70.0	61.0	67.0	61.0

^a NCHS public use data file for the total US.
 - Statistic could not be calculated.

Table I-14 - continued
MEDIAN AGE OF CANCER PATIENTS AT DEATH^a, 1997-2001
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	71.0	-	71.0	71.0	-	71.0	68.0	-	68.0
Cervix uteri	57.0	-	57.0	57.0	-	57.0	58.0	-	58.0
Corpus uteri	73.0	-	73.0	74.0	-	74.0	71.0	-	71.0
Uterus, NOS	74.0	-	74.0	75.0	-	75.0	70.0	-	70.0
Ovary	71.0	-	71.0	72.0	-	72.0	68.0	-	68.0
Vagina	75.0	-	75.0	76.0	-	76.0	70.0	-	70.0
Vulva	79.0	-	79.0	80.0	-	80.0	72.0	-	72.0
Other female genital system	71.0	-	71.0	72.0	-	72.0	67.0	-	67.0
Male Genital System:	79.0	79.0	-	80.0	80.0	-	77.0	77.0	-
Prostate	79.0	79.0	-	80.0	80.0	-	77.0	77.0	-
Testis	39.0	39.0	-	39.0	39.0	-	39.0	39.0	-
Penis	71.0	71.0	-	71.0	71.0	-	68.0	68.0	-
Other male genital system	74.5	74.5	-	75.0	75.0	-	67.0	67.0	-
Urinary System:	75.0	73.0	77.0	75.0	74.0	77.0	71.0	69.0	73.0
Urinary bladder	78.0	77.0	80.0	78.0	77.0	80.0	75.0	74.0	77.0
Kidney & renal pelvis	71.0	69.0	74.0	71.0	70.0	74.0	67.0	65.0	70.0
Ureter	76.0	75.0	78.0	76.0	75.0	78.0	73.0	72.5	74.0
Other urinary system	76.0	75.0	76.0	77.0	75.0	78.0	66.0	69.0	66.0
Eye & Orbit	71.0	68.0	73.0	72.0	69.0	74.0	47.5	44.0	49.0
Brain & Nervous System:	64.0	62.0	66.0	65.0	63.0	67.0	58.0	55.0	61.0
Endocrine System:	69.0	65.0	72.0	70.0	66.0	73.0	62.0	56.0	65.0
Thyroid	74.0	70.0	76.0	74.0	71.0	76.0	69.0	64.5	71.5
Other endocrine & thymus	57.0	56.0	59.0	59.0	57.0	60.0	47.5	42.5	50.0
Lymphoma:	73.0	71.0	75.0	74.0	72.0	76.0	63.0	60.0	67.0
Hodgkin lymphoma	60.0	56.0	64.0	62.0	59.0	66.0	41.0	42.0	41.0
Non-Hodgkin lymphoma	73.0	71.0	76.0	74.0	72.0	76.0	64.0	61.0	68.0
Myeloma	74.0	73.0	75.0	74.0	73.0	76.0	71.0	70.0	72.0
Leukemia:	73.0	72.0	75.0	74.0	73.0	76.0	67.0	65.0	69.0
Lymphocytic:	75.0	73.0	78.0	76.0	74.0	79.0	69.0	67.0	72.0
Acute lymphocytic	47.0	42.0	53.0	49.0	45.0	55.0	34.0	30.5	39.0
Chronic lymphocytic	78.0	76.0	81.0	78.0	76.0	81.0	73.0	71.0	76.0
Other lymphocytic	77.0	76.0	80.0	78.0	76.0	80.5	73.0	70.0	75.0
Myeloid & Monocytic:	71.0	71.0	72.0	72.0	71.0	73.0	63.0	61.0	65.0
Acute myeloid	71.0	71.0	71.0	72.0	71.0	72.0	64.0	63.0	65.0
Chronic myeloid	70.0	68.0	71.0	71.0	70.0	73.0	57.0	53.0	63.0
Acute monocytic	74.5	73.0	76.0	75.0	74.0	76.0	59.5	64.5	55.0
Other myeloid & monocytic	76.0	76.0	77.0	76.0	76.0	78.0	72.0	71.0	74.5
Other:	76.0	74.0	77.0	76.0	75.0	78.0	70.0	69.0	72.0
Other acute	75.0	74.0	76.0	75.0	74.0	76.0	69.0	69.0	70.0
Aleukemic, subleuk & NOS	77.0	75.0	79.0	77.0	75.0	79.0	71.0	69.0	72.5
Ill-defined & unspecified	73.0	72.0	75.0	74.0	72.0	76.0	69.0	66.0	71.0

^a NCHS public use data file for the total US.

- Statistic could not be calculated.

Table I-15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site, Race and Sex

12 SEER Areas, 1999-2001

Site	All Races		Whites		Blacks	
	Males	Females	Males	Females	Males	Females
All Sites	45.59	38.18	46.02	39.55	42.45	31.76
Invasive and In Situ	46.82	41.53	47.39	43.07	42.80	33.98
Oral cavity and Pharynx	1.37	0.67	1.38	0.68	1.32	0.50
Esophagus	0.77	0.26	0.79	0.25	0.76	0.36
Stomach	1.23	0.77	1.07	0.63	1.27	0.99
Colon and Rectum	5.90	5.54	5.95	5.52	4.92	5.39
Invasive and In Situ	6.23	5.79	6.26	5.76	5.25	5.68
Liver and Intrahepatic bile duct	0.88	0.42	0.72	0.35	0.91	0.36
Pancreas	1.24	1.23	1.25	1.20	1.25	1.35
Larynx	0.63	0.16	0.64	0.16	0.88	0.22
Invasive and In Situ	0.69	0.17	0.70	0.17	0.92	0.23
Lung and Bronchus	7.63	5.71	7.63	5.99	8.20	5.29
Melanoma of skin	1.89	1.28	2.27	1.55	0.10	0.06
Invasive and In Situ	3.02	2.06	3.59	2.48	0.12	0.10
Breast	0.12	13.39	0.12	14.21	0.16	9.99
Invasive and In Situ	0.13	15.96	0.14	16.88	0.18	12.02
Cervix uteri	-	0.77	-	0.74	-	0.95
Corpus and Uterus, NOS	-	2.62	-	2.82	-	1.74
Invasive and In Situ	-	2.66	-	2.87	-	1.76
Ovary	-	1.48	-	1.60	-	0.91
Prostate	17.81	-	17.58	-	20.58	-
Testis	0.35	-	0.42	-	0.10	-
Urinary bladder(Invasive and In Situ)	3.56	1.13	3.97	1.22	1.42	0.81
Kidney and Renal pelvis	1.49	0.90	1.57	0.93	1.35	0.92
Brain and Other nervous system	0.67	0.51	0.75	0.57	0.33	0.28
Thyroid	0.33	0.90	0.35	0.94	0.16	0.49
Hodgkin lymphoma	0.23	0.19	0.25	0.21	0.21	0.14
Non-Hodgkin lymphoma	2.18	1.80	2.31	1.91	1.21	1.04
Multiple myeloma	0.66	0.55	0.65	0.51	0.92	0.93
Leukemia	1.47	1.04	1.58	1.11	0.88	0.79
Acute Lymphocytic Leukemia	0.12	0.10	0.13	0.11	0.05	0.06
Chronic Lymphocytic Leukemia	0.50	0.31	0.55	0.34	0.28	0.20
Acute Myeloid Leukemia	0.45	0.35	0.47	0.36	0.30	0.29
Chronic Myeloid Leukemia	0.20	0.14	0.20	0.14	0.14	0.10

Devcan Version 5.2, April 2004, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Note: Invasive cancer only unless specified otherwise.

Table I-16

Lifetime Risk (Percent) of Dying from Cancer by Site, Race and Sex

Total U.S., 1999-2001

Site	All Races		Whites		Blacks	
	Males	Females	Males	Females	Males	Females
All Sites	23.66	19.99	23.71	20.22	24.34	19.47
Oral cavity and Pharynx	0.38	0.19	0.36	0.19	0.52	0.18
Esophagus	0.73	0.22	0.73	0.21	0.83	0.31
Stomach	0.60	0.40	0.54	0.36	0.91	0.67
Colon and Rectum	2.39	2.27	2.39	2.24	2.44	2.56
Liver and Intrahepatic bile duct	0.62	0.36	0.59	0.34	0.66	0.39
Pancreas	1.16	1.17	1.17	1.16	1.14	1.32
Larynx	0.24	0.06	0.22	0.06	0.38	0.09
Lung and Bronchus	7.29	4.84	7.36	5.02	7.36	3.92
Melanoma of skin	0.35	0.19	0.40	0.22	0.03	0.05
Breast	0.03	2.98	0.03	2.99	0.05	3.25
Cervix uteri	-	0.27	-	0.24	-	0.47
Corpus and Uterus, NOS	-	0.50	-	0.48	-	0.73
Ovary	-	1.03	-	1.08	-	0.73
Prostate	3.01	-	2.82	-	4.73	-
Testis	0.02	-	0.02	-	0.01	-
Urinary bladder	0.74	0.31	0.79	0.32	0.38	0.32
Kidney and Renal pelvis	0.57	0.34	0.59	0.35	0.45	0.28
Brain and Other nervous system	0.49	0.39	0.53	0.42	0.23	0.21
Thyroid	0.04	0.06	0.05	0.06	0.03	0.06
Hodgkin lymphoma	0.05	0.04	0.05	0.04	0.03	0.03
Non-Hodgkin lymphoma	0.95	0.83	1.01	0.89	0.50	0.43
Multiple myeloma	0.45	0.41	0.43	0.38	0.63	0.68
Leukemia	0.96	0.72	1.01	0.75	0.63	0.54
Acute Lymphocytic Leukemia	0.05	0.04	0.05	0.04	0.03	0.02
Chronic Lymphocytic Leukemia	0.23	0.16	0.24	0.16	0.16	0.11
Acute Myeloid Leukemia	0.31	0.25	0.33	0.26	0.19	0.17
Chronic Myeloid Leukemia	0.07	0.06	0.07	0.06	0.06	0.05

Table I-17
 US AND SEER DEATH RATES BY PRIMARY CANCER SITE AND RACE/ETHNICITY, 1992-2001

Site		Total United States ^a							SEER 12 Areas ^a						
		Total	White	Black	AI/AN ^b	API ^c	Hisp ^d	W-NHisp ^d	Total	White	Black	AI/AN ^b	API ^c	Hisp ^d	W-NHisp ^d
All Sites	Both Sexes	205.2	201.8	261.5	136.2	126.6	138.1	204.5	191.2	191.5	250.9	143.7	137.7	137.8	196.5
	Male	260.6	254.3	364.7	168.1	157.9	177.1	257.9	236.7	235.2	337.0	172.8	173.7	173.0	240.3
	Female	169.9	168.6	200.1	115.1	103.0	112.4	170.5	162.4	164.5	198.9	123.5	110.0	115.7	169.3
Oral Cavity & Pharynx	Both Sexes	3.0	2.8	4.8	2.3	2.6	1.9	2.9	2.9	2.8	4.1	3.4	3.0	1.7	2.9
	Male	4.6	4.2	8.4	3.7	3.9	3.3	4.3	4.3	4.0	7.0	5.6	4.5	2.8	4.2
	Female	1.7	1.7	2.2	1.2	1.4	0.9	1.7	1.8	1.8	2.0	1.7	1.7	0.8	1.9
Esophagus	Both Sexes	4.3	4.0	7.5	2.7	2.2	2.5	4.1	4.1	4.0	6.6	3.3	2.4	2.3	4.1
	Male	7.6	7.1	13.2	4.7	3.7	4.5	7.3	7.0	6.9	11.1	5.6	4.3	4.3	7.1
	Female	1.8	1.6	3.5	1.1	0.9	0.9	1.6	1.8	1.7	3.5	1.6	0.9	0.8	1.8
Stomach	Both Sexes	5.0	4.4	9.7	5.5	10.0	7.4	4.1	5.7	4.8	9.2	7.9	11.0	8.7	4.2
	Male	7.2	6.4	14.3	7.6	13.0	10.1	6.0	8.1	6.9	13.3	11.1	14.6	11.9	6.1
	Female	3.5	3.0	6.7	4.1	7.7	5.5	2.8	4.0	3.3	6.3	5.5	8.2	6.5	2.8
Colon & Rectum	Both Sexes	21.8	21.3	28.8	13.7	13.6	14.2	21.4	20.2	19.9	27.6	15.4	15.3	14.1	20.3
	Male	26.6	26.1	35.0	16.1	16.4	18.1	26.2	24.4	24.3	33.1	16.6	18.7	18.3	24.6
	Female	18.5	18.0	24.9	12.0	11.4	11.5	18.0	17.1	16.9	24.2	14.4	12.5	11.3	17.2
Liver & Intrahepatic Bile Duct	Both Sexes	4.4	4.0	6.0	5.6	10.8	7.1	3.8	4.9	4.1	6.1	6.7	10.9	7.1	3.8
	Male	6.4	5.8	9.1	7.7	15.9	10.1	5.5	7.3	6.0	9.4	8.9	16.2	10.1	5.4
	Female	2.9	2.7	3.7	4.1	6.6	4.8	2.6	3.1	2.7	3.7	5.2	6.6	4.8	2.5
Pancreas	Both Sexes	10.6	10.3	14.5	6.2	7.5	8.4	10.3	10.4	10.2	14.8	7.2	8.1	8.5	10.3
	Male	12.3	12.0	16.6	6.2	8.5	9.5	12.0	11.8	11.7	16.2	7.7	9.4	9.1	11.9
	Female	9.2	8.9	12.9	6.0	6.7	7.5	8.9	9.2	9.0	13.5	6.7	7.1	7.9	9.1
Larynx	Both Sexes	1.5	1.3	2.9	1.1	0.5	1.1	1.3	1.3	1.2	2.7	1.1	0.5	0.9	1.2
	Male	2.7	2.5	5.8	2.0	1.0	2.3	2.4	2.3	2.2	5.2	2.3	1.0	1.8	2.2
	Female	0.5	0.5	1.0	0.5	0.1	0.2	0.5	0.5	0.5	0.9	0.3	0.1	0.2	0.5
Lung & Bronchus	Both Sexes	57.3	57.1	67.4	36.6	29.0	25.7	59.2	49.4	49.9	65.6	32.8	31.9	23.8	52.8
	Male	81.6	80.0	110.7	51.0	41.6	40.9	82.7	67.0	66.3	101.5	45.7	46.3	36.1	69.3
	Female	40.2	41.0	39.2	26.2	19.2	14.8	42.5	37.0	38.5	41.6	23.2	20.7	15.3	41.3
Melanoma of the Skin	Both Sexes	2.7	3.0	0.5	0.6	0.4	0.8	3.2	2.4	2.9	0.4	0.4	0.4	0.8	3.2
	Male	3.9	4.4	0.5	0.8	0.5	1.1	4.6	3.5	4.1	0.4	0.6	0.6	0.9	4.6
	Female	1.8	2.0	0.5	0.4	0.3	0.6	2.1	1.6	1.9	0.4	0.3	0.3	0.6	2.1
Breast	Female	28.8	28.3	36.4	14.5	12.9	17.9	28.6	27.8	28.3	36.7	16.6	14.9	17.7	29.4

^a NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^b American Indian/Alaskan Native.

^c Asian/Pacific Islander.

^d Mortality data for Hispanics (Hisp) and White Non-Hispanics (W-NHisp) do not include cases from Connecticut, Maine, Maryland, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

- Statistic could not be calculated.

Table I-17 - continued
 US AND SEER DEATH RATES BY PRIMARY CANCER SITE AND RACE/ETHNICITY, 1992-2001

Site		Total United States ^a							SEER 12 Areas ^a						
		Total	White	Black	AI/AN ^b	API ^c	Hispanic ^d	W-NHispanic ^d	Total	White	Black	AI/AN ^b	API ^c	Hispanic ^d	W-NHispanic ^d
Cervix	Female	3.1	2.7	6.3	3.2	3.0	3.9	2.6	2.7	2.5	4.8	2.7	2.8	4.0	2.3
Corpus & Uterus, NOS	Female	4.1	3.9	7.0	2.5	2.2	3.2	3.9	4.1	4.0	6.3	2.5	2.5	3.2	4.1
Ovary	Female	9.0	9.3	7.6	5.1	4.7	6.3	9.4	9.0	9.6	7.0	6.0	5.0	6.5	10.1
Prostate	Male	34.6	31.8	74.9	22.3	14.7	25.0	32.1	32.5	31.6	67.8	18.4	15.7	25.1	32.4
Testis	Male	0.3	0.3	0.1	0.2	0.1	0.3	0.3	0.3	0.3	0.1	0.4	0.1	0.3	0.3
Urinary Bladder	Both Sexes	4.4	4.5	4.0	1.6	1.8	2.4	4.5	4.1	4.3	4.0	1.6	2.0	2.3	4.4
	Male	7.7	8.0	5.9	2.5	2.9	4.2	8.1	7.0	7.6	5.9	2.6	3.1	3.6	7.9
	Female	2.3	2.3	3.0	1.0	1.1	1.3	2.3	2.2	2.3	2.9	1.0	1.1	1.4	2.3
Kidney & Renal Pelvis	Both Sexes	4.2	4.3	4.2	4.8	1.9	3.8	4.3	3.9	4.0	4.0	5.4	2.2	3.7	4.1
	Male	6.2	6.2	6.2	6.7	2.7	5.5	6.3	5.6	5.9	5.7	7.5	3.2	5.3	5.9
	Female	2.8	2.9	2.8	3.4	1.2	2.5	2.9	2.6	2.7	2.7	3.9	1.3	2.5	2.7
Brain & Nervous System	Both Sexes	4.7	5.0	2.7	2.0	1.9	2.9	5.2	4.5	5.0	2.9	2.0	2.2	3.0	5.3
	Male	5.7	6.1	3.3	2.5	2.3	3.5	6.3	5.6	6.2	3.4	2.5	2.6	3.5	6.6
	Female	3.8	4.1	2.3	1.6	1.6	2.5	4.3	3.6	4.0	2.5	1.7	1.8	2.6	4.3
Thyroid	Both Sexes	0.5	0.5	0.4	0.3	0.7	0.6	0.4	0.5	0.5	0.3	0.5	0.8	0.8	0.4
	Male	0.4	0.4	0.3	0.2	0.5	0.4	0.4	0.4	0.4	0.3	0.4	0.6	0.6	0.4
	Female	0.5	0.5	0.5	0.4	0.8	0.7	0.4	0.5	0.5	0.4	0.6	0.9	1.0	0.4
Hodgkin Lymphoma	Both Sexes	0.5	0.5	0.5	0.2	0.2	0.6	0.5	0.5	0.6	0.5	0.1	0.2	0.6	0.6
	Male	0.7	0.7	0.6	0.2	0.2	0.8	0.7	0.7	0.7	0.7	0.1	0.2	0.8	0.7
	Female	0.4	0.4	0.4	0.2	0.1	0.4	0.4	0.4	0.4	0.4	0.1	0.1	0.5	0.4
Non-Hodgkin Lymphoma	Both Sexes	8.4	8.8	5.8	4.6	5.3	6.5	8.9	8.2	8.7	5.7	4.2	5.7	6.5	8.9
	Male	10.5	10.9	7.5	5.4	6.8	8.1	11.0	10.2	10.8	7.2	5.5	7.6	8.2	11.1
	Female	6.9	7.2	4.5	4.0	4.2	5.3	7.3	6.7	7.2	4.7	3.2	4.3	5.3	7.3
Myeloma	Both Sexes	3.9	3.6	7.6	3.0	1.8	3.1	3.6	3.8	3.7	7.6	3.2	1.9	3.4	3.8
	Male	4.8	4.5	9.2	3.5	2.2	3.8	4.5	4.7	4.7	8.6	4.0	2.3	4.1	4.8
	Female	3.2	2.9	6.6	2.7	1.5	2.7	3.0	3.2	3.0	7.0	2.6	1.6	2.9	3.1
Leukemia	Both Sexes	7.8	7.9	7.0	4.1	4.3	5.3	8.0	7.5	7.8	7.1	3.6	4.8	5.4	8.0
	Male	10.4	10.7	9.4	5.2	5.5	6.7	10.8	10.0	10.5	9.2	4.6	6.2	6.6	10.9
	Female	6.0	6.1	5.5	3.4	3.4	4.4	6.1	5.8	6.0	5.7	3.0	3.8	4.5	6.1

^a NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.

^b American Indian/Alaskan Native.

^c Asian/Pacific Islander.

^d Mortality data for Hispanics (Hispanic) and White Non-Hispanics (W-NHispanic) do not include cases from Connecticut, Maine, Maryland, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

- Statistic could not be calculated.

Table I-18
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2001^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			26-Year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d
All Sites	3,765,929	3,839,441	4,120,783	9,048,822	9,220,361
Male	1,898,532	1,924,231	2,057,870	4,163,637	4,212,021
Female	1,867,397	1,915,210	2,062,913	4,885,185	5,008,340
Oral Cavity & Pharynx	82,674	93,488	95,948	206,494	224,986
Male	55,409	62,109	63,607	133,057	143,709
Female	27,265	31,379	32,341	73,437	81,277
Esophagus	15,737	18,638	18,650	22,081	25,810
Male	11,952	13,945	13,945	16,515	19,027
Female	3,785	4,693	4,705	5,566	6,783
Stomach	29,431	34,023	34,105	55,827	62,559
Male	17,724	20,593	20,627	32,088	36,017
Female	11,707	13,430	13,478	23,739	26,542
Colon & Rectum	403,032	460,916	468,964	968,947	1,070,487
Male	201,690	231,008	234,709	471,439	517,261
Female	201,342	229,908	234,255	497,508	553,226
Liver & Intrahep	10,956	12,582	12,593	14,108	15,944
Male	7,118	8,193	8,204	8,706	9,905
Female	3,838	4,389	4,389	5,402	6,039
Pancreas	18,095	21,156	21,156	23,967	27,543
Male	8,680	10,372	10,372	11,163	13,073
Female	9,415	10,784	10,784	12,804	14,470
Larynx	34,076	39,252	39,432	92,464	101,321
Male	26,759	30,913	31,046	74,006	80,900
Female	7,317	8,339	8,386	18,458	20,421
Lung & Bronchus	201,687	243,497	247,320	330,991	388,538
Male	101,771	123,706	125,522	165,394	193,505
Female	99,916	119,791	121,798	165,597	195,033
Melanoma of the Skin	194,560	214,066	219,641	544,920	578,885
Male	103,566	115,336	118,977	269,150	287,927
Female	90,994	98,730	100,664	275,770	290,958
Breast					
Female	791,033	846,865	880,990	2,058,593	2,184,125
Cervix					
Female	46,131	48,226	48,288	174,429	179,437
Corpus & Uterus					
Female	140,432	157,422	157,475	474,773	510,266

^a US 2001 cancer prevalence counts are based on 2001 cancer prevalence proportions from the SEER 9 registries and 1/1/2001 US population estimates based on the average of 2000 and 2001 population estimates from the US Bureau of the Census.

^{b,c,d,e} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 26 years (1975-2000); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1996-2000). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1997; Melanoma in 1998.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred 20 years ago.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 1997 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence.

In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1998 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table I-18 - continued
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2001^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			26-Year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d
Ovary					
Female	53,367	61,207	61,212	137,976	153,863
Prostate					
Male	854,021	920,213	920,281	1,721,366	1,838,653
Testis					
Male	36,654	37,256	37,808	136,928	138,606
Urinary Bladder					
Male	182,170	217,670	218,962	460,530	521,945
Female	136,806	163,071	164,170	341,794	385,549
Female	45,364	54,599	54,792	118,736	136,396
Kidney & Renal Pelvis					
Male	85,215	102,069	102,742	196,981	225,128
Female	51,234	62,053	62,545	116,559	133,919
Female	33,981	40,016	40,197	80,422	91,209
Brain & Nervous System					
Male	34,921	36,642	36,751	87,853	90,304
Female	19,339	20,344	20,376	47,814	49,141
Female	15,582	16,298	16,375	40,039	41,163
Thyroid					
Male	82,780	88,485	88,667	261,607	273,642
Female	19,086	20,927	20,976	59,817	63,033
Female	63,694	67,558	67,691	201,790	210,609
Hodgkin Lymphoma					
Male	33,445	34,715	34,726	120,684	123,181
Female	17,766	18,435	18,435	62,988	64,279
Female	15,679	16,280	16,291	57,696	58,902
Non-Hodgkin Lymphoma					
Male	149,775	169,517	169,968	316,297	346,749
Female	78,674	89,136	89,398	163,797	178,734
Female	71,101	80,381	80,570	152,500	168,015
Myeloma					
Male	34,489	39,418	39,430	48,987	54,930
Female	18,725	21,516	21,528	26,710	30,013
Female	15,764	17,902	17,902	22,277	24,917
Leukemia					
Male	76,511	85,522	85,546	173,859	187,285
Female	43,969	49,297	49,309	97,991	105,642
Female	32,542	36,225	36,237	75,868	81,643
Acute Lymphocytic Leuk					
Male	13,506	13,685	13,685	42,330	42,610
Female	7,536	7,633	7,633	23,174	23,304
Female	5,970	6,052	6,052	19,156	19,306
Childhood (0-19)					
Male	54,418	54,527	54,800	204,131	204,569
Female	28,817	28,871	29,025	104,636	104,829
Female	25,601	25,656	25,775	99,495	99,740

^a US 2001 cancer prevalence counts are based on 2001 cancer prevalence proportions from the SEER 9 registries and 1/1/2001 US population estimates based on the average of 2000 and 2001 population estimates from the US Bureau of the Census.

^{bcde} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 26 years (1975-2000); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1996-2000). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1997; Melanoma in 1998.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred 20 years ago.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 1997 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence.

In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1998 melanoma is counted for 5-year limited duration prevalence for melanoma.

Surveillance, Epidemiology, and End Results Program, 2004

National Cancer Institute

U.S.A



Leading Causes of Death in US Percent of All Causes of Death 1975 vs 2001





Figure 1-2

Source: NCHS public use data file for the total US.

US Death Rates 1975-2001

Ages Less Than 65



Ages 65 and Over





Figure 1-3

Source: NCHS public use data file for the total US. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.

Trends in SEER Incidence & US Death Rates by Primary Cancer Site 1992-2001

Trends in SEER Incidence Rates



Trends in US Cancer Death Rates




Figure 1-4

Source: SEER 12 areas and NCHS public use data file for the total US. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.

The APC is the Annual Percent Change over the time interval.

* The APC is significantly different from zero ($p < .05$).

Trends in SEER Incidence Rates by Primary Cancer Site 1992-2001




Figure 1-5

Source: SEER 12 areas. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.
The APC is the Annual Percent Change over the time interval.
* The APC is significantly different from zero ($p < .05$).

Trends in US Death Rates by Primary Cancer Site 1992-2001




Figure 1-6

Source: NCHS public use data file for the total US. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.

The APC is the Annual Percent Change over the time interval.

* The APC is significantly different from zero ($p < .05$).

Trends in SEER Incidence Rates by Primary Cancer Site 1992-2001




Figure 1-7

Source: SEER 12 areas. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.
 The APC is the Annual Percent Change over the time interval.
 * The APC is significantly different from zero ($p < .05$).

Trends in US Death Rates by Primary Cancer Site 1992-2001




Figure 1-8

Source: NCHS public use data file for the total US. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups. The APC is the Annual Percent Change over the time interval.
* The APC is significantly different from zero ($p < .05$).

SEER Incidence* and US Death Rates,# 1997-2001 5-Year Relative Survival Rates,^ 1995-2000 All Cancer Combined, by Race and Sex





Figure 1-9

* Incidence rates are from the SEER 12 areas and are age-adjusted to the 2000 US standard population by 5-year age groups.

Death rates are from the NCHS public use data file for the total US and are age-adjusted to the 2000 US standard population by 5-year age groups.

^ Survival rates are from the SEER 9 areas. Relative survival rates are expressed as percents.


Trends in US Death Rates, 1992-2001 by Primary Cancer Site All Ages, by Race



Source: NCHS public use data file for the total US.
The APC is the Annual Percent Change over the time interval.

Figure I-11

5-Year Relative Survival Rates SEER Program, 1995-2000 Both Sexes, by Race




Source: SEER 9 areas.


SEER Cancer Incidence and US Death Rates, 1997-2001 By Cancer Site and Race

Incidence Cancer Site Mortality


Lung and Bronchus




Colon and Rectum



Breast (Female)



Prostate



Source: SEER 12 areas and NCHS public use data file for the total US.

^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics excludes Detroit and Hawaii. Mortality data for Hispanics excludes cases from Connecticut, Maine, Maryland, Oklahoma, New York, North Dakota, New Hampshire, and Vermont.

Rates are per 100,000 and age-adjusted to the 2000 U.S. standard population by 5-year age groups.

SEER Incidence 1992-2001 Males by Race/Ethnicity




Figure 1-13

Source: SEER 12 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, and Alaska). Incidence data for Hispanics does not include cases from Detroit and Hawaii.

Regression lines are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute.

^^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

SEER Incidence 1992-2001 Females by Race/Ethnicity




Figure 1-14

Source: SEER 12 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, and Alaska). Incidence data for Hispanics does not include cases from Detroit and Hawaii.

Regression lines are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute.

^^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

US Mortality 1992-2001 Males by Race/Ethnicity




Figure 1-15

Source: NCHS public use data file for the total US. Mortality data for Hispanics does not include cases from Connecticut, Maine, Maryland, New York, New Hampshire, North Dakota, Oklahoma, and Vermont.
 Regression lines are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute.
 ^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

US Mortality 1992-2001 Females by Race/Ethnicity




Figure 1-16

Source: NCHS public use data file for the total US. Mortality data for Hispanics does not include cases from Connecticut, Maine, Maryland, New York, New Hampshire, North Dakota, Oklahoma, and Vermont.

Regression lines are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute.

^^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence Percent Change, 1992-2001

Numbers (burden) vs Rates (risk)

All Ages




Figure 1-17

US Incidence estimates based on SEER age-specific rates applied to US population.

Mortality Percent Change, 1992-2001 Numbers (burden) vs Rates (risk) All Ages





Figure I-18

US Mortality estimates based on US age-specific rates applied to US population.

Person-Years of Life Lost Due to Cancer, All Races Both Sexes, 2001



Average Years of Life Lost Per Person Dying of Cancer All Races, Both Sexes, 2001





Figure I-19

Source: NCHS public use data file for the total US and 2000 Life Tables.

Person-Years of Life Lost Due to Major Causes of Death in US All Races, Both Sexes, 2001



Average Years of Life Lost Per Person Due to Major Causes of Death in US All Races, Both Sexes, 2001




Figure I-20

Source: NCHS public use data file for the total US and 2000 Life Tables.

* Human Immunodeficiency Virus

SEER Incidence and Delay Adjusted Incidence Rates+ All Cancer Sites, By Sex




Figure 1-21

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero ($p < 0.05$).

SEER Incidence and Delay Adjusted Incidence Rates+ Both Sexes





Figure 1-22

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.

* The APC is significantly different from zero ($p < 0.05$).

SEER Incidence and Delay Adjusted Incidence Rates⁺ Males




Figure I-23

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero ($p < 0.05$).

SEER Incidence and Delay Adjusted Incidence Rates⁺ Females




Figure I-24

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 2.7, September 2003, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero ($p < 0.05$).